A roadmap towards Ireland’s membership of BBMRI-ERIC

A roadmap towards Ireland’s membership of... | HRB Open Research dataLayer = dataLayer || []; // Standard GTM initialization - Google Consent Mode handles consent automatically (function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start': new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0], j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src= 'https://www.googletagmanager.com/gtm.js?id='+i+dl+ '>m_auth=hzk0Vc3qFsQYhCrIoHz68A>m_preview=env-1>m_cookies_win=x';f.parentNode.insertBefore(j,f); })(window,document,'script','dataLayer','GTM-MWFK8L5J'); ;window.NREUM||(NREUM={});NREUM.init={distributed_tracing:{enabled:true},privacy:{cookies_enabled:true},ajax:{deny_list:["bam.nr-data.net"]}}; ;NREUM.loader_config={accountID:"438030",trustKey:"438030",agentID:"772317073",licenseKey:"97f8f67f26",applicationID:"772317073"} ;NREUM.info={beacon:"bam.nr-data.net",errorBeacon:"bam.nr-data.net",licenseKey:"97f8f67f26",applicationID:"772317073",sa:1} ;/*! For license information please see nr-loader-spa-1.236.0.min.js.LICENSE.txt */ (()=>{"use strict";var e,t,r={5763:(e,t,r)=>{r.d(t,{P_:()=>l,Mt:()=>g,C5:()=>s,DL:()=>v,OP:()=>T,lF:()=>D,Yu:()=>y,Dg:()=>h,CX:()=>c,GE:()=>b,sU:()=>_});var n=r(8632),i=r(9567);const o={beacon:n.ce.beacon,errorBeacon:n.ce.errorBeacon,licenseKey:void 0,applicationID:void 0,sa:void 0,queueTime:void 0,applicationTime:void 0,ttGuid:void 0,user:void 0,account:void 0,product:void 0,extra:void 0,jsAttributes:{},userAttributes:void 0,atts:void 0,transactionName:void 0,tNamePlain:void 0},a={};function s(e){if(!e)throw new Error("All info objects require an agent identifier!");if(!a[e])throw new Error("Info for ".concat(e," was never set"));return a[e]}function c(e,t){if(!e)throw new Error("All info objects require an agent identifier!");a[e]=(0,i.D)(t,o),(0,n.Qy)(e,a[e],"info")}var u=r(7056);const d=()=>{const e={blockSelector:"[data-nr-block]",maskInputOptions:{password:!0}};return{allow_bfcache:!0,privacy:{cookies_enabled:!0},ajax:{deny_list:void 0,enabled:!0,harvestTimeSeconds:10},distributed_tracing:{enabled:void 0,exclude_newrelic_header:void 0,cors_use_newrelic_header:void 0,cors_use_tracecontext_headers:void 0,allowed_origins:void 0},session:{domain:void 0,expiresMs:u.oD,inactiveMs:u.Hb},ssl:void 0,obfuscate:void 0,jserrors:{enabled:!0,harvestTimeSeconds:10},metrics:{enabled:!0},page_action:{enabled:!0,harvestTimeSeconds:30},page_view_event:{enabled:!0},page_view_timing:{enabled:!0,harvestTimeSeconds:30,long_task:!1},session_trace:{enabled:!0,harvestTimeSeconds:10},harvest:{tooManyRequestsDelay:60},session_replay:{enabled:!1,harvestTimeSeconds:60,sampleRate:.1,errorSampleRate:.1,maskTextSelector:"*",maskAllInputs:!0,get blockClass(){return"nr-block"},get ignoreClass(){return"nr-ignore"},get maskTextClass(){return"nr-mask"},get blockSelector(){return e.blockSelector},set blockSelector(t){e.blockSelector+=",".concat(t)},get maskInputOptions(){return e.maskInputOptions},set maskInputOptions(t){e.maskInputOptions={...t,password:!0}}},spa:{enabled:!0,harvestTimeSeconds:10}}},f={};function l(e){if(!e)throw new Error("All configuration objects require an agent identifier!");if(!f[e])throw new Error("Configuration for ".concat(e," was never set"));return f[e]}function h(e,t){if(!e)throw new Error("All configuration objects require an agent identifier!");f[e]=(0,i.D)(t,d()),(0,n.Qy)(e,f[e],"config")}function g(e,t){if(!e)throw new Error("All configuration objects require an agent identifier!");var r=l(e);if(r){for(var n=t.split("."),i=0;i {r.d(t,{D:()=>i});var n=r(50);function i(e,t){try{if(!e||"object"!=typeof e)return(0,n.Z)("Setting a Configurable requires an object as input");if(!t||"object"!=typeof t)return(0,n.Z)("Setting a Configurable requires a model to set its initial properties");const r=Object.create(Object.getPrototypeOf(t),Object.getOwnPropertyDescriptors(t)),o=0===Object.keys(r).length?e:r;for(let a in o)if(void 0!==e[a])try{"object"==typeof e[a]&&"object"==typeof t[a]?r[a]=i(e[a],t[a]):r[a]=e[a]}catch(e){(0,n.Z)("An error occurred while setting a property of a Configurable",e)}return r}catch(e){(0,n.Z)("An error occured while setting a Configurable",e)}}},6818:(e,t,r)=>{r.d(t,{Re:()=>i,gF:()=>o,q4:()=>n});const n="1.236.0",i="PROD",o="CDN"},385:(e,t,r)=>{r.d(t,{FN:()=>a,IF:()=>u,Nk:()=>f,Tt:()=>s,_A:()=>o,il:()=>n,pL:()=>c,v6:()=>i,w1:()=>d});const n="undefined"!=typeof window&&!!window.document,i="undefined"!=typeof WorkerGlobalScope&&("undefined"!=typeof self&&self instanceof WorkerGlobalScope&&self.navigator instanceof WorkerNavigator||"undefined"!=typeof globalThis&&globalThis instanceof WorkerGlobalScope&&globalThis.navigator instanceof WorkerNavigator),o=n?window:"undefined"!=typeof WorkerGlobalScope&&("undefined"!=typeof self&&self instanceof WorkerGlobalScope&&self||"undefined"!=typeof globalThis&&globalThis instanceof WorkerGlobalScope&&globalThis),a=""+o?.location,s=/iPad|iPhone|iPod/.test(navigator.userAgent),c=s&&"undefined"==typeof SharedWorker,u=(()=>{const e=navigator.userAgent.match(/Firefox[/\s](\d+\.\d+)/);return Array.isArray(e)&&e.length>=2?+e[1]:0})(),d=Boolean(n&&window.document.documentMode),f=!!navigator.sendBeacon},1117:(e,t,r)=>{r.d(t,{w:()=>o});var n=r(50);const i={agentIdentifier:"",ee:void 0};class o{constructor(e){try{if("object"!=typeof e)return(0,n.Z)("shared context requires an object as input");this.sharedContext={},Object.assign(this.sharedContext,i),Object.entries(e).forEach((e=>{let[t,r]=e;Object.keys(i).includes(t)&&(this.sharedContext[t]=r)}))}catch(e){(0,n.Z)("An error occured while setting SharedContext",e)}}}},8e3:(e,t,r)=>{r.d(t,{L:()=>d,R:()=>c});var n=r(2177),i=r(1284),o=r(4322),a=r(3325);const s={};function c(e,t){const r={staged:!1,priority:a.p[t]||0};u(e),s[e].get(t)||s[e].set(t,r)}function u(e){e&&(s[e]||(s[e]=new Map))}function d(){let e=arguments.length>0&&void 0!==arguments[0]?arguments[0]:"",t=arguments.length>1&&void 0!==arguments[1]?arguments[1]:"feature";if(u(e),!e||!s[e].get(t))return a(t);s[e].get(t).staged=!0;const r=[...s[e]];function a(t){const r=e?n.ee.get(e):n.ee,a=o.X.handlers;if(r.backlog&&a){var s=r.backlog[t],c=a[t];if(c){for(var u=0;s&&u {let[t,r]=e;return r.staged}))&&(r.sort(((e,t)=>e[1].priority-t[1].priority)),r.forEach((e=>{let[t]=e;a(t)})))}function f(e,t){var r=e[1];(0,i.D)(t[r],(function(t,r){var n=e[0];if(r[0]===n){var i=r[1],o=e[3],a=e[2];i.apply(o,a)}}))}},2177:(e,t,r)=>{r.d(t,{c:()=>f,ee:()=>u});var n=r(8632),i=r(2210),o=r(1284),a=r(5763),s="nr@context";let c=(0,n.fP)();var u;function d(){}function f(e){return(0,i.X)(e,s,l)}function l(){return new d}function h(){u.aborted=!0,u.backlog={}}c.ee?u=c.ee:(u=function e(t,r){var n={},c={},f={},g=!1;try{g=16===r.length&&(0,a.OP)(r).isolatedBacklog}catch(e){}var p={on:b,addEventListener:b,removeEventListener:y,emit:v,get:x,listeners:w,context:m,buffer:A,abort:h,aborted:!1,isBuffering:E,debugId:r,backlog:g?{}:t&&"object"==typeof t.backlog?t.backlog:{}};return p;function m(e){return e&&e instanceof d?e:e?(0,i.X)(e,s,l):l()}function v(e,r,n,i,o){if(!1!==o&&(o=!0),!u.aborted||i){t&&o&&t.emit(e,r,n);for(var a=m(n),s=w(e),d=s.length,f=0;fn,p:()=>i});var n=r(2177).ee.get("handle");function i(e,t,r,i,o){o?(o.buffer([e],i),o.emit(e,t,r)):(n.buffer([e],i),n.emit(e,t,r))}},4322:(e,t,r)=>{r.d(t,{X:()=>o});var n=r(5546);o.on=a;var i=o.handlers={};function o(e,t,r,o){a(o||n.E,i,e,t,r)}function a(e,t,r,i,o){o||(o="feature"),e||(e=n.E);var a=t[o]=t[o]||{};(a[r]=a[r]||[]).push([e,i])}},3239:(e,t,r)=>{r.d(t,{bP:()=>s,iz:()=>c,m$:()=>a});var n=r(385);let i=!1,o=!1;try{const e={get passive(){return i=!0,!1},get signal(){return o=!0,!1}};n._A.addEventListener("test",null,e),n._A.removeEventListener("test",null,e)}catch(e){}function a(e,t){return i||o?{capture:!!e,passive:i,signal:t}:!!e}function s(e,t){let r=arguments.length>2&&void 0!==arguments[2]&&arguments[2],n=arguments.length>3?arguments[3]:void 0;window.addEventListener(e,t,a(r,n))}function c(e,t){let r=arguments.length>2&&void 0!==arguments[2]&&arguments[2],n=arguments.length>3?arguments[3]:void 0;document.addEventListener(e,t,a(r,n))}},4402:(e,t,r)=>{r.d(t,{Ht:()=>u,M:()=>c,Rl:()=>a,ky:()=>s});var n=r(385);const i="xxxxxxxx-xxxx-4xxx-yxxx-xxxxxxxxxxxx";function o(e,t){return e?15&e[t]:16*Math.random()|0}function a(){const e=n._A?.crypto||n._A?.msCrypto;let t,r=0;return e&&e.getRandomValues&&(t=e.getRandomValues(new Uint8Array(31))),i.split("").map((e=>"x"===e?o(t,++r).toString(16):"y"===e?(3&o()|8).toString(16):e)).join("")}function s(e){const t=n._A?.crypto||n._A?.msCrypto;let r,i=0;t&&t.getRandomValues&&(r=t.getRandomValues(new Uint8Array(31)));const a=[];for(var s=0;s {r.d(t,{Bq:()=>n,Hb:()=>o,oD:()=>i});const n="NRBA",i=144e5,o=18e5},7894:(e,t,r)=>{function n(){return Math.round(performance.now())}r.d(t,{z:()=>n})},7243:(e,t,r)=>{r.d(t,{e:()=>o});var n=r(385),i={};function o(e){if(e in i)return i[e];if(0===(e||"").indexOf("data:"))return{protocol:"data"};let t;var r=n._A?.location,o={};if(n.il)t=document.createElement("a"),t.href=e;else try{t=new URL(e,r.href)}catch(e){return o}o.port=t.port;var a=t.href.split("://");!o.port&&a[1]&&(o.port=a[1].split("/")[0].split("@").pop().split(":")[1]),o.port&&"0"!==o.port||(o.port="https"===a[0]?"443":"80"),o.hostname=t.hostname||r.hostname,o.pathname=t.pathname,o.protocol=a[0],"/"!==o.pathname.charAt(0)&&(o.pathname="/"+o.pathname);var s=!t.protocol||":"===t.protocol||t.protocol===r.protocol,c=t.hostname===r.hostname&&t.port===r.port;return o.sameOrigin=s&&(!t.hostname||c),"/"===o.pathname&&(i[e]=o),o}},50:(e,t,r)=>{function n(e,t){"function"==typeof console.warn&&(console.warn("New Relic: ".concat(e)),t&&console.warn(t))}r.d(t,{Z:()=>n})},2587:(e,t,r)=>{r.d(t,{N:()=>c,T:()=>u});var n=r(2177),i=r(5546),o=r(8e3),a=r(3325);const s={stn:[a.D.sessionTrace],err:[a.D.jserrors,a.D.metrics],ins:[a.D.pageAction],spa:[a.D.spa],sr:[a.D.sessionReplay,a.D.sessionTrace]};function c(e,t){const r=n.ee.get(t);e&&"object"==typeof e&&(Object.entries(e).forEach((e=>{let[t,n]=e;void 0===u[t]&&(s[t]?s[t].forEach((e=>{n?(0,i.p)("feat-"+t,[],void 0,e,r):(0,i.p)("block-"+t,[],void 0,e,r),(0,i.p)("rumresp-"+t,[Boolean(n)],void 0,e,r)})):n&&(0,i.p)("feat-"+t,[],void 0,void 0,r),u[t]=Boolean(n))})),Object.keys(s).forEach((e=>{void 0===u[e]&&(s[e]?.forEach((t=>(0,i.p)("rumresp-"+e,[!1],void 0,t,r))),u[e]=!1)})),(0,o.L)(t,a.D.pageViewEvent))}const u={}},2210:(e,t,r)=>{r.d(t,{X:()=>i});var n=Object.prototype.hasOwnProperty;function i(e,t,r){if(n.call(e,t))return e[t];var i=r();if(Object.defineProperty&&Object.keys)try{return Object.defineProperty(e,t,{value:i,writable:!0,enumerable:!1}),i}catch(e){}return e[t]=i,i}},1284:(e,t,r)=>{r.d(t,{D:()=>n});const n=(e,t)=>Object.entries(e||{}).map((e=>{let[r,n]=e;return t(r,n)}))},4351:(e,t,r)=>{r.d(t,{P:()=>o});var n=r(2177);const i=()=>{const e=new WeakSet;return(t,r)=>{if("object"==typeof r&&null!==r){if(e.has(r))return;e.add(r)}return r}};function o(e){try{return JSON.stringify(e,i())}catch(e){try{n.ee.emit("internal-error",[e])}catch(e){}}}},3960:(e,t,r)=>{r.d(t,{K:()=>a,b:()=>o});var n=r(3239);function i(){return"undefined"==typeof document||"complete"===document.readyState}function o(e,t){if(i())return e();(0,n.bP)("load",e,t)}function a(e){if(i())return e();(0,n.iz)("DOMContentLoaded",e)}},8632:(e,t,r)=>{r.d(t,{EZ:()=>u,Qy:()=>c,ce:()=>o,fP:()=>a,gG:()=>d,mF:()=>s});var n=r(7894),i=r(385);const o={beacon:"bam.nr-data.net",errorBeacon:"bam.nr-data.net"};function a(){return i._A.NREUM||(i._A.NREUM={}),void 0===i._A.newrelic&&(i._A.newrelic=i._A.NREUM),i._A.NREUM}function s(){let e=a();return e.o||(e.o={ST:i._A.setTimeout,SI:i._A.setImmediate,CT:i._A.clearTimeout,XHR:i._A.XMLHttpRequest,REQ:i._A.Request,EV:i._A.Event,PR:i._A.Promise,MO:i._A.MutationObserver,FETCH:i._A.fetch}),e}function c(e,t,r){let i=a();const o=i.initializedAgents||{},s=o[e]||{};return Object.keys(s).length||(s.initializedAt={ms:(0,n.z)(),date:new Date}),i.initializedAgents={...o,[e]:{...s,[r]:t}},i}function u(e,t){a()[e]=t}function d(){return function(){let e=a();const t=e.info||{};e.info={beacon:o.beacon,errorBeacon:o.errorBeacon,...t}}(),function(){let e=a();const t=e.init||{};e.init={...t}}(),s(),function(){let e=a();const t=e.loader_config||{};e.loader_config={...t}}(),a()}},7956:(e,t,r)=>{r.d(t,{N:()=>i});var n=r(3239);function i(e){let t=arguments.length>1&&void 0!==arguments[1]&&arguments[1],r=arguments.length>2?arguments[2]:void 0,i=arguments.length>3?arguments[3]:void 0;return void(0,n.iz)("visibilitychange",(function(){if(t)return void("hidden"==document.visibilityState&&e());e(document.visibilityState)}),r,i)}},1214:(e,t,r)=>{r.d(t,{em:()=>v,u5:()=>N,QU:()=>S,_L:()=>I,Gm:()=>L,Lg:()=>M,gy:()=>U,BV:()=>Q,Kf:()=>ee});var n=r(2177);const i="nr@original";var o=Object.prototype.hasOwnProperty,a=!1;function s(e,t){return e||(e=n.ee),r.inPlace=function(e,t,n,i,o){n||(n="");var a,s,c,u="-"===n.charAt(0);for(c=0;c 2?n-2:0),o=2;o {r(A[T],e,w),r(E[T],e,w)})),r(l._A,"fetch",y),t.on(y+"end",(function(e,r){var n=this;if(r){var i=r.headers.get("content-length");null!==i&&(n.rxSize=i),t.emit(y+"done",[null,r],n)}else t.emit(y+"done",[e],n)})),t}const O={},j=["pushState","replaceState"];function S(e){const t=function(e){return(e||n.ee).get("history")}(e);return!l.il||O[t.debugId]++||(O[t.debugId]=1,s(t).inPlace(window.history,j,"-")),t}var P=r(3239);const C={},R=["appendChild","insertBefore","replaceChild"];function I(e){const t=function(e){return(e||n.ee).get("jsonp")}(e);if(!l.il||C[t.debugId])return t;C[t.debugId]=!0;var r=s(t),i=/[?&](?:callback|cb)=([^&#]+)/,o=/(.*)\.([^.]+)/,a=/^(\w+)(\.|$)(.*)$/;function c(e,t){var r=e.match(a),n=r[1],i=r[3];return i?c(i,t[n]):t[n]}return r.inPlace(Node.prototype,R,"dom-"),t.on("dom-start",(function(e){!function(e){if(!e||"string"!=typeof e.nodeName||"script"!==e.nodeName.toLowerCase())return;if("function"!=typeof e.addEventListener)return;var n=(a=e.src,s=a.match(i),s?s[1]:null);var a,s;if(!n)return;var u=function(e){var t=e.match(o);if(t&&t.length>=3)return{key:t[2],parent:c(t[1],window)};return{key:e,parent:window}}(n);if("function"!=typeof u.parent[u.key])return;var d={};function f(){t.emit("jsonp-end",[],d),e.removeEventListener("load",f,(0,P.m$)(!1)),e.removeEventListener("error",l,(0,P.m$)(!1))}function l(){t.emit("jsonp-error",[],d),t.emit("jsonp-end",[],d),e.removeEventListener("load",f,(0,P.m$)(!1)),e.removeEventListener("error",l,(0,P.m$)(!1))}r.inPlace(u.parent,[u.key],"cb-",d),e.addEventListener("load",f,(0,P.m$)(!1)),e.addEventListener("error",l,(0,P.m$)(!1)),t.emit("new-jsonp",[e.src],d)}(e[0])})),t}var k=r(5763);const H={};function L(e){const t=function(e){return(e||n.ee).get("mutation")}(e);if(!l.il||H[t.debugId])return t;H[t.debugId]=!0;var r=s(t),i=k.Yu.MO;return i&&(window.MutationObserver=function(e){return this instanceof i?new i(r(e,"fn-")):i.apply(this,arguments)},MutationObserver.prototype=i.prototype),t}const z={};function M(e){const t=function(e){return(e||n.ee).get("promise")}(e);if(z[t.debugId])return t;z[t.debugId]=!0;var r=n.c,o=s(t),a=k.Yu.PR;return a&&function(){function e(r){var n=t.context(),i=o(r,"executor-",n,null,!1);const s=Reflect.construct(a,[i],e);return t.context(s).getCtx=function(){return n},s}l._A.Promise=e,Object.defineProperty(e,"name",{value:"Promise"}),e.toString=function(){return a.toString()},Object.setPrototypeOf(e,a),["all","race"].forEach((function(r){const n=a[r];e[r]=function(e){let i=!1;[...e||[]].forEach((e=>{this.resolve(e).then(a("all"===r),a(!1))}));const o=n.apply(this,arguments);return o;function a(e){return function(){t.emit("propagate",[null,!i],o,!1,!1),i=i||!e}}}})),["resolve","reject"].forEach((function(r){const n=a[r];e[r]=function(e){const r=n.apply(this,arguments);return e!==r&&t.emit("propagate",[e,!0],r,!1,!1),r}})),e.prototype=a.prototype;const n=a.prototype.then;a.prototype.then=function(){var e=this,i=r(e);i.promise=e;for(var a=arguments.length,s=new Array(a),c=0;c e())),t};function m(e,t){i.inPlace(t,["onreadystatechange"],"fn-",E)}function b(){var e=this,t=r.context(e);e.readyState>3&&!t.resolved&&(t.resolved=!0,r.emit("xhr-resolved",[],e)),i.inPlace(e,f,"fn-",E)}if(function(e,t){for(var r in e)t[r]=e[r]}(o,p),p.prototype=o.prototype,i.inPlace(p.prototype,J,"-xhr-",E),r.on("send-xhr-start",(function(e,t){m(e,t),function(e){h.push(e),a&&(y?y.then(A):u?u(A):(w=-w,x.data=w))}(t)})),r.on("open-xhr-start",m),a){var y=c&&c.resolve();if(!u&&!c){var w=1,x=document.createTextNode(w);new a(A).observe(x,{characterData:!0})}}else t.on("fn-end",(function(e){e[0]&&e[0].type===d||A()}));function A(){for(var e=0;e {r.d(t,{t:()=>n});const n=r(3325).D.ajax},6660:(e,t,r)=>{r.d(t,{A:()=>i,t:()=>n});const n=r(3325).D.jserrors,i="nr@seenError"},3081:(e,t,r)=>{r.d(t,{gF:()=>o,mY:()=>i,t9:()=>n,vz:()=>s,xS:()=>a});const n=r(3325).D.metrics,i="sm",o="cm",a="storeSupportabilityMetrics",s="storeEventMetrics"},4649:(e,t,r)=>{r.d(t,{t:()=>n});const n=r(3325).D.pageAction},7633:(e,t,r)=>{r.d(t,{Dz:()=>i,OJ:()=>a,qw:()=>o,t9:()=>n});const n=r(3325).D.pageViewEvent,i="firstbyte",o="domcontent",a="windowload"},9251:(e,t,r)=>{r.d(t,{t:()=>n});const n=r(3325).D.pageViewTiming},3614:(e,t,r)=>{r.d(t,{BST_RESOURCE:()=>i,END:()=>s,FEATURE_NAME:()=>n,FN_END:()=>u,FN_START:()=>c,PUSH_STATE:()=>d,RESOURCE:()=>o,START:()=>a});const n=r(3325).D.sessionTrace,i="bstResource",o="resource",a="-start",s="-end",c="fn"+a,u="fn"+s,d="pushState"},7836:(e,t,r)=>{r.d(t,{BODY:()=>A,CB_END:()=>E,CB_START:()=>u,END:()=>x,FEATURE_NAME:()=>i,FETCH:()=>_,FETCH_BODY:()=>v,FETCH_DONE:()=>m,FETCH_START:()=>p,FN_END:()=>c,FN_START:()=>s,INTERACTION:()=>l,INTERACTION_API:()=>d,INTERACTION_EVENTS:()=>o,JSONP_END:()=>b,JSONP_NODE:()=>g,JS_TIME:()=>T,MAX_TIMER_BUDGET:()=>a,REMAINING:()=>f,SPA_NODE:()=>h,START:()=>w,originalSetTimeout:()=>y});var n=r(5763);const i=r(3325).D.spa,o=["click","submit","keypress","keydown","keyup","change"],a=999,s="fn-start",c="fn-end",u="cb-start",d="api-ixn-",f="remaining",l="interaction",h="spaNode",g="jsonpNode",p="fetch-start",m="fetch-done",v="fetch-body-",b="jsonp-end",y=n.Yu.ST,w="-start",x="-end",A="-body",E="cb"+x,T="jsTime",_="fetch"},5938:(e,t,r)=>{r.d(t,{W:()=>o});var n=r(5763),i=r(2177);class o{constructor(e,t,r){this.agentIdentifier=e,this.aggregator=t,this.ee=i.ee.get(e,(0,n.OP)(this.agentIdentifier).isolatedBacklog),this.featureName=r,this.blocked=!1}}},9144:(e,t,r)=>{r.d(t,{j:()=>m});var n=r(3325),i=r(5763),o=r(5546),a=r(2177),s=r(7894),c=r(8e3),u=r(3960),d=r(385),f=r(50),l=r(3081),h=r(8632);function g(){const e=(0,h.gG)();["setErrorHandler","finished","addToTrace","inlineHit","addRelease","addPageAction","setCurrentRouteName","setPageViewName","setCustomAttribute","interaction","noticeError","setUserId"].forEach((t=>{e[t]=function(){for(var r=arguments.length,n=new Array(r),i=0;i 1?r-1:0),i=1;i {e.exposed&&e.api[t]&&o.push(e.api[t](...n))})),o.length>1?o:o[0]}(t,...n)}}))}var p=r(2587);function m(e){let t=arguments.length>1&&void 0!==arguments[1]?arguments[1]:{},m=arguments.length>2?arguments[2]:void 0,v=arguments.length>3?arguments[3]:void 0,{init:b,info:y,loader_config:w,runtime:x={loaderType:m},exposed:A=!0}=t;const E=(0,h.gG)();y||(b=E.init,y=E.info,w=E.loader_config),(0,i.Dg)(e,b||{}),(0,i.GE)(e,w||{}),(0,i.sU)(e,x),y.jsAttributes??={},d.v6&&(y.jsAttributes.isWorker=!0),(0,i.CX)(e,y),g();const T=function(e,t){t||(0,c.R)(e,"api");const h={};var g=a.ee.get(e),p=g.get("tracer"),m="api-",v=m+"ixn-";function b(t,r,n,o){const a=(0,i.C5)(e);return null===r?delete a.jsAttributes[t]:(0,i.CX)(e,{...a,jsAttributes:{...a.jsAttributes,[t]:r}}),x(m,n,!0,o||null===r?"session":void 0)(t,r)}function y(){}["setErrorHandler","finished","addToTrace","inlineHit","addRelease"].forEach((e=>h[e]=x(m,e,!0,"api"))),h.addPageAction=x(m,"addPageAction",!0,n.D.pageAction),h.setCurrentRouteName=x(m,"routeName",!0,n.D.spa),h.setPageViewName=function(t,r){if("string"==typeof t)return"/"!==t.charAt(0)&&(t="/"+t),(0,i.OP)(e).customTransaction=(r||"http://custom.transaction")+t,x(m,"setPageViewName",!0)()},h.setCustomAttribute=function(e,t){let r=arguments.length>2&&void 0!==arguments[2]&&arguments[2];if("string"==typeof e){if(["string","number"].includes(typeof t)||null===t)return b(e,t,"setCustomAttribute",r);(0,f.Z)("Failed to execute setCustomAttribute.\nNon-null value must be a string or number type, but a type of was provided."))}else(0,f.Z)("Failed to execute setCustomAttribute.\nName must be a string type, but a type of was provided."))},h.setUserId=function(e){if("string"==typeof e||null===e)return b("enduser.id",e,"setUserId",!0);(0,f.Z)("Failed to execute setUserId.\nNon-null value must be a string type, but a type of was provided."))},h.interaction=function(){return(new y).get()};var w=y.prototype={createTracer:function(e,t){var r={},i=this,a="function"==typeof t;return(0,o.p)(v+"tracer",[(0,s.z)(),e,r],i,n.D.spa,g),function(){if(p.emit((a?"":"no-")+"fn-start",[(0,s.z)(),i,a],r),a)try{return t.apply(this,arguments)}catch(e){throw p.emit("fn-err",[arguments,this,"string"==typeof e?new Error(e):e],r),e}finally{p.emit("fn-end",[(0,s.z)()],r)}}}};function x(e,t,r,i){return function(){return(0,o.p)(l.xS,["API/"+t+"/called"],void 0,n.D.metrics,g),i&&(0,o.p)(e+t,[(0,s.z)(),...arguments],r?null:this,i,g),r?void 0:this}}function A(){r.e(439).then(r.bind(r,7438)).then((t=>{let{setAPI:r}=t;r(e),(0,c.L)(e,"api")})).catch((()=>(0,f.Z)("Downloading runtime APIs failed...")))}return["actionText","setName","setAttribute","save","ignore","onEnd","getContext","end","get"].forEach((e=>{w[e]=x(v,e,void 0,n.D.spa)})),h.noticeError=function(e,t){"string"==typeof e&&(e=new Error(e)),(0,o.p)(l.xS,["API/noticeError/called"],void 0,n.D.metrics,g),(0,o.p)("err",[e,(0,s.z)(),!1,t],void 0,n.D.jserrors,g)},d.il?(0,u.b)((()=>A()),!0):A(),h}(e,v);return(0,h.Qy)(e,T,"api"),(0,h.Qy)(e,A,"exposed"),(0,h.EZ)("activatedFeatures",p.T),T}},3325:(e,t,r)=>{r.d(t,{D:()=>n,p:()=>i});const n={ajax:"ajax",jserrors:"jserrors",metrics:"metrics",pageAction:"page_action",pageViewEvent:"page_view_event",pageViewTiming:"page_view_timing",sessionReplay:"session_replay",sessionTrace:"session_trace",spa:"spa"},i={[n.pageViewEvent]:1,[n.pageViewTiming]:2,[n.metrics]:3,[n.jserrors]:4,[n.ajax]:5,[n.sessionTrace]:6,[n.pageAction]:7,[n.spa]:8,[n.sessionReplay]:9}}},n={};function i(e){var t=n[e];if(void 0!==t)return t.exports;var o=n[e]={exports:{}};return r[e](o,o.exports,i),o.exports}i.m=r,i.d=(e,t)=>{for(var r in t)i.o(t,r)&&!i.o(e,r)&&Object.defineProperty(e,r,{enumerable:!0,get:t[r]})},i.f={},i.e=e=>Promise.all(Object.keys(i.f).reduce(((t,r)=>(i.f[r](e,t),t)),[])),i.u=e=>(({78:"page_action-aggregate",147:"metrics-aggregate",242:"session-manager",317:"jserrors-aggregate",348:"page_view_timing-aggregate",412:"lazy-feature-loader",439:"async-api",538:"recorder",590:"session_replay-aggregate",675:"compressor",733:"session_trace-aggregate",786:"page_view_event-aggregate",873:"spa-aggregate",898:"ajax-aggregate"}[e]||e)+"."+{78:"ac76d497",147:"3dc53903",148:"1a20d5fe",242:"2a64278a",317:"49e41428",348:"bd6de33a",412:"2f55ce66",439:"30bd804e",538:"1b18459f",590:"cf0efb30",675:"ae9f91a8",733:"83105561",786:"06482edd",860:"03a8b7a5",873:"e6b09d52",898:"998ef92b"}[e]+"-1.236.0.min.js"),i.o=(e,t)=>Object.prototype.hasOwnProperty.call(e,t),e={},t="NRBA:",i.l=(r,n,o,a)=>{if(e[r])e[r].push(n);else{var s,c;if(void 0!==o)for(var u=document.getElementsByTagName("script"),d=0;d {s.onerror=s.onload=null,clearTimeout(h);var i=e[r];if(delete e[r],s.parentNode&&s.parentNode.removeChild(s),i&&i.forEach((e=>e(n))),t)return t(n)},h=setTimeout(l.bind(null,void 0,{type:"timeout",target:s}),12e4);s.onerror=l.bind(null,s.onerror),s.onload=l.bind(null,s.onload),c&&document.head.appendChild(s)}},i.r=e=>{"undefined"!=typeof Symbol&&Symbol.toStringTag&&Object.defineProperty(e,Symbol.toStringTag,{value:"Module"}),Object.defineProperty(e,"__esModule",{value:!0})},i.j=364,i.p="https://js-agent.newrelic.com/",(()=>{var e={364:0,953:0};i.f.j=(t,r)=>{var n=i.o(e,t)?e[t]:void 0;if(0!==n)if(n)r.push(n[2]);else{var o=new Promise(((r,i)=>n=e[t]=[r,i]));r.push(n[2]=o);var a=i.p+i.u(t),s=new Error;i.l(a,(r=>{if(i.o(e,t)&&(0!==(n=e[t])&&(e[t]=void 0),n)){var o=r&&("load"===r.type?"missing":r.type),a=r&&r.target&&r.target.src;s.message="Loading chunk "+t+" failed.\n("+o+": "+a+")",s.name="ChunkLoadError",s.type=o,s.request=a,n[1](s)}}),"chunk-"+t,t)}};var t=(t,r)=>{var n,o,[a,s,c]=r,u=0;if(a.some((t=>0!==e[t]))){for(n in s)i.o(s,n)&&(i.m[n]=s[n]);if(c)c(i)}for(t&&t(r);u {i.r(o);var e=i(3325),t=i(5763);const r=Object.values(e.D);function n(e){const n={};return r.forEach((r=>{n[r]=function(e,r){return!1!==(0,t.Mt)(r,"".concat(e,".enabled"))}(r,e)})),n}var a=i(9144);var s=i(5546),c=i(385),u=i(8e3),d=i(5938),f=i(3960),l=i(50);class h extends d.W{constructor(e,t,r){let n=!(arguments.length>3&&void 0!==arguments[3])||arguments[3];super(e,t,r),this.auto=n,this.abortHandler,this.featAggregate,this.onAggregateImported,n&&(0,u.R)(e,r)}importAggregator(){let e=arguments.length>0&&void 0!==arguments[0]?arguments[0]:{};if(this.featAggregate||!this.auto)return;const r=c.il&&!0===(0,t.Mt)(this.agentIdentifier,"privacy.cookies_enabled");let n;this.onAggregateImported=new Promise((e=>{n=e}));const o=async()=>{let t;try{if(r){const{setupAgentSession:e}=await Promise.all([i.e(860),i.e(242)]).then(i.bind(i,3228));t=e(this.agentIdentifier)}}catch(e){(0,l.Z)("A problem occurred when starting up session manager. This page will not start or extend any session.",e)}try{if(!this.shouldImportAgg(this.featureName,t))return void(0,u.L)(this.agentIdentifier,this.featureName);const{lazyFeatureLoader:r}=await i.e(412).then(i.bind(i,8582)),{Aggregate:o}=await r(this.featureName,"aggregate");this.featAggregate=new o(this.agentIdentifier,this.aggregator,e),n(!0)}catch(e){(0,l.Z)("Downloading and initializing ".concat(this.featureName," failed..."),e),this.abortHandler?.(),n(!1)}};c.il?(0,f.b)((()=>o()),!0):o()}shouldImportAgg(r,n){return r!==e.D.sessionReplay||!1!==(0,t.Mt)(this.agentIdentifier,"session_trace.enabled")&&(!!n?.isNew||!!n?.state.sessionReplay)}}var g=i(7633),p=i(7894);class m extends h{static featureName=g.t9;constructor(r,n){let i=!(arguments.length>2&&void 0!==arguments[2])||arguments[2];if(super(r,n,g.t9,i),("undefined"==typeof PerformanceNavigationTiming||c.Tt)&&"undefined"!=typeof PerformanceTiming){const n=(0,t.OP)(r);n[g.Dz]=Math.max(Date.now()-n.offset,0),(0,f.K)((()=>n[g.qw]=Math.max((0,p.z)()-n[g.Dz],0))),(0,f.b)((()=>{const t=(0,p.z)();n[g.OJ]=Math.max(t-n[g.Dz],0),(0,s.p)("timing",["load",t],void 0,e.D.pageViewTiming,this.ee)}))}this.importAggregator()}}var v=i(1117),b=i(1284);class y extends v.w{constructor(e){super(e),this.aggregatedData={}}store(e,t,r,n,i){var o=this.getBucket(e,t,r,i);return o.metrics=function(e,t){t||(t={count:0});return t.count+=1,(0,b.D)(e,(function(e,r){t[e]=w(r,t[e])})),t}(n,o.metrics),o}merge(e,t,r,n,i){var o=this.getBucket(e,t,n,i);if(o.metrics){var a=o.metrics;a.count+=r.count,(0,b.D)(r,(function(e,t){if("count"!==e){var n=a[e],i=r[e];i&&!i.c?a[e]=w(i.t,n):a[e]=function(e,t){if(!t)return e;t.c||(t=x(t.t));return t.min=Math.min(e.min,t.min),t.max=Math.max(e.max,t.max),t.t+=e.t,t.sos+=e.sos,t.c+=e.c,t}(i,a[e])}}))}else o.metrics=r}storeMetric(e,t,r,n){var i=this.getBucket(e,t,r);return i.stats=w(n,i.stats),i}getBucket(e,t,r,n){this.aggregatedData[e]||(this.aggregatedData[e]={});var i=this.aggregatedData[e][t];return i||(i=this.aggregatedData[e][t]={params:r||{}},n&&(i.custom=n)),i}get(e,t){return t?this.aggregatedData[e]&&this.aggregatedData[e][t]:this.aggregatedData[e]}take(e){for(var t={},r="",n=!1,i=0;i t.max&&(t.max=e),e 2&&void 0!==arguments[2])||arguments[2];super(e,r,j.t,n),c.il&&((0,t.OP)(e).initHidden=Boolean("hidden"===document.visibilityState),(0,N.N)((()=>(0,s.p)("docHidden",[(0,p.z)()],void 0,j.t,this.ee)),!0),(0,O.bP)("pagehide",(()=>(0,s.p)("winPagehide",[(0,p.z)()],void 0,j.t,this.ee))),this.importAggregator())}}var P=i(3081);class C extends h{static featureName=P.t9;constructor(e,t){let r=!(arguments.length>2&&void 0!==arguments[2])||arguments[2];super(e,t,P.t9,r),this.importAggregator()}}var R,I=i(2210),k=i(1214),H=i(2177),L={};try{R=localStorage.getItem("__nr_flags").split(","),console&&"function"==typeof console.log&&(L.console=!0,-1!==R.indexOf("dev")&&(L.dev=!0),-1!==R.indexOf("nr_dev")&&(L.nrDev=!0))}catch(e){}function z(e){try{L.console&&z(e)}catch(e){}}L.nrDev&&H.ee.on("internal-error",(function(e){z(e.stack)})),L.dev&&H.ee.on("fn-err",(function(e,t,r){z(r.stack)})),L.dev&&(z("NR AGENT IN DEVELOPMENT MODE"),z("flags: "+(0,b.D)(L,(function(e,t){return e})).join(", ")));var M=i(6660);class B extends h{static featureName=M.t;constructor(r,n){let i=!(arguments.length>2&&void 0!==arguments[2])||arguments[2];super(r,n,M.t,i),this.skipNext=0;try{this.removeOnAbort=new AbortController}catch(e){}const o=this;o.ee.on("fn-start",(function(e,t,r){o.abortHandler&&(o.skipNext+=1)})),o.ee.on("fn-err",(function(t,r,n){o.abortHandler&&!n[M.A]&&((0,I.X)(n,M.A,(function(){return!0})),this.thrown=!0,(0,s.p)("err",[n,(0,p.z)()],void 0,e.D.jserrors,o.ee))})),o.ee.on("fn-end",(function(){o.abortHandler&&!this.thrown&&o.skipNext>0&&(o.skipNext-=1)})),o.ee.on("internal-error",(function(t){(0,s.p)("ierr",[t,(0,p.z)(),!0],void 0,e.D.jserrors,o.ee)})),this.origOnerror=c._A.onerror,c._A.onerror=this.onerrorHandler.bind(this),c._A.addEventListener("unhandledrejection",(t=>{const r=function(e){let t="Unhandled Promise Rejection: ";if(e instanceof Error)try{return e.message=t+e.message,e}catch(t){return e}if(void 0===e)return new Error(t);try{return new Error(t+(0,D.P)(e))}catch(e){return new Error(t)}}(t.reason);(0,s.p)("err",[r,(0,p.z)(),!1,{unhandledPromiseRejection:1}],void 0,e.D.jserrors,this.ee)}),(0,O.m$)(!1,this.removeOnAbort?.signal)),(0,k.gy)(this.ee),(0,k.BV)(this.ee),(0,k.em)(this.ee),(0,t.OP)(r).xhrWrappable&&(0,k.Kf)(this.ee),this.abortHandler=this.#e,this.importAggregator()}#e(){this.removeOnAbort?.abort(),this.abortHandler=void 0}onerrorHandler(t,r,n,i,o){"function"==typeof this.origOnerror&&this.origOnerror(...arguments);try{this.skipNext?this.skipNext-=1:(0,s.p)("err",[o||new F(t,r,n),(0,p.z)()],void 0,e.D.jserrors,this.ee)}catch(t){try{(0,s.p)("ierr",[t,(0,p.z)(),!0],void 0,e.D.jserrors,this.ee)}catch(e){}}return!1}}function F(e,t,r){this.message=e||"Uncaught error with no additional information",this.sourceURL=t,this.line=r}let U=1;const q="nr@id";function G(e){const t=typeof e;return!e||"object"!==t&&"function"!==t?-1:e===c._A?0:(0,I.X)(e,q,(function(){return U++}))}function V(e){if("string"==typeof e&&e.length)return e.length;if("object"==typeof e){if("undefined"!=typeof ArrayBuffer&&e instanceof ArrayBuffer&&e.byteLength)return e.byteLength;if("undefined"!=typeof Blob&&e instanceof Blob&&e.size)return e.size;if(!("undefined"!=typeof FormData&&e instanceof FormData))try{return(0,D.P)(e).length}catch(e){return}}}var X=i(7243);class W{constructor(e){this.agentIdentifier=e,this.generateTracePayload=this.generateTracePayload.bind(this),this.shouldGenerateTrace=this.shouldGenerateTrace.bind(this)}generateTracePayload(e){if(!this.shouldGenerateTrace(e))return null;var r=(0,t.DL)(this.agentIdentifier);if(!r)return null;var n=(r.accountID||"").toString()||null,i=(r.agentID||"").toString()||null,o=(r.trustKey||"").toString()||null;if(!n||!i)return null;var a=(0,_.M)(),s=(0,_.Ht)(),c=Date.now(),u={spanId:a,traceId:s,timestamp:c};return(e.sameOrigin||this.isAllowedOrigin(e)&&this.useTraceContextHeadersForCors())&&(u.traceContextParentHeader=this.generateTraceContextParentHeader(a,s),u.traceContextStateHeader=this.generateTraceContextStateHeader(a,c,n,i,o)),(e.sameOrigin&&!this.excludeNewrelicHeader()||!e.sameOrigin&&this.isAllowedOrigin(e)&&this.useNewrelicHeaderForCors())&&(u.newrelicHeader=this.generateTraceHeader(a,s,c,n,i,o)),u}generateTraceContextParentHeader(e,t){return"00-"+t+"-"+e+"-01"}generateTraceContextStateHeader(e,t,r,n,i){return i+"@nr=0-1-"+r+"-"+n+"-"+e+"----"+t}generateTraceHeader(e,t,r,n,i,o){if(!("function"==typeof c._A?.btoa))return null;var a={v:[0,1],d:{ty:"Browser",ac:n,ap:i,id:e,tr:t,ti:r}};return o&&n!==o&&(a.d.tk=o),btoa((0,D.P)(a))}shouldGenerateTrace(e){return this.isDtEnabled()&&this.isAllowedOrigin(e)}isAllowedOrigin(e){var r=!1,n={};if((0,t.Mt)(this.agentIdentifier,"distributed_tracing")&&(n=(0,t.P_)(this.agentIdentifier).distributed_tracing),e.sameOrigin)r=!0;else if(n.allowed_origins instanceof Array)for(var i=0;i 2&&void 0!==arguments[2])||arguments[2];super(r,n,Z.t,i),(0,t.OP)(r).xhrWrappable&&(this.dt=new W(r),this.handler=(e,t,r,n)=>(0,s.p)(e,t,r,n,this.ee),(0,k.u5)(this.ee),(0,k.Kf)(this.ee),function(r,n,i,o){function a(e){var t=this;t.totalCbs=0,t.called=0,t.cbTime=0,t.end=E,t.ended=!1,t.xhrGuids={},t.lastSize=null,t.loadCaptureCalled=!1,t.params=this.params||{},t.metrics=this.metrics||{},e.addEventListener("load",(function(r){_(t,e)}),(0,O.m$)(!1)),c.IF||e.addEventListener("progress",(function(e){t.lastSize=e.loaded}),(0,O.m$)(!1))}function s(e){this.params={method:e[0]},T(this,e[1]),this.metrics={}}function u(e,n){var i=(0,t.DL)(r);i.xpid&&this.sameOrigin&&n.setRequestHeader("X-NewRelic-ID",i.xpid);var a=o.generateTracePayload(this.parsedOrigin);if(a){var s=!1;a.newrelicHeader&&(n.setRequestHeader("newrelic",a.newrelicHeader),s=!0),a.traceContextParentHeader&&(n.setRequestHeader("traceparent",a.traceContextParentHeader),a.traceContextStateHeader&&n.setRequestHeader("tracestate",a.traceContextStateHeader),s=!0),s&&(this.dt=a)}}function d(e,t){var r=this.metrics,i=e[0],o=this;if(r&&i){var a=V(i);a&&(r.txSize=a)}this.startTime=(0,p.z)(),this.listener=function(e){try{"abort"!==e.type||o.loadCaptureCalled||(o.params.aborted=!0),("load"!==e.type||o.called===o.totalCbs&&(o.onloadCalled||"function"!=typeof t.onload)&&"function"==typeof o.end)&&o.end(t)}catch(e){try{n.emit("internal-error",[e])}catch(e){}}};for(var s=0;s 1?e[1]=i:e.push(i)}else e[0]&&e[0].headers&&s(e[0].headers,n)&&(this.dt=n);function s(e,t){var r=!1;return t.newrelicHeader&&(e.set("newrelic",t.newrelicHeader),r=!0),t.traceContextParentHeader&&(e.set("traceparent",t.traceContextParentHeader),t.traceContextStateHeader&&e.set("tracestate",t.traceContextStateHeader),r=!0),r}}function x(e,t){this.params={},this.metrics={},this.startTime=(0,p.z)(),this.dt=t,e.length>=1&&(this.target=e[0]),e.length>=2&&(this.opts=e[1]);var r,n=this.opts||{},i=this.target;"string"==typeof i?r=i:"object"==typeof i&&i instanceof Y?r=i.url:c._A?.URL&&"object"==typeof i&&i instanceof URL&&(r=i.href),T(this,r);var o=(""+(i&&i instanceof Y&&i.method||n.method||"GET")).toUpperCase();this.params.method=o,this.txSize=V(n.body)||0}function A(t,r){var n;this.endTime=(0,p.z)(),this.params||(this.params={}),this.params.status=r?r.status:0,"string"==typeof this.rxSize&&this.rxSize.length>0&&(n=+this.rxSize);var o={txSize:this.txSize,rxSize:n,duration:(0,p.z)()-this.startTime};i("xhr",[this.params,o,this.startTime,this.endTime,"fetch"],this,e.D.ajax)}function E(t){var r=this.params,n=this.metrics;if(!this.ended){this.ended=!0;for(var o=0;o 2&&void 0!==arguments[2])||arguments[2];super(e,t,we.t,r),this.importAggregator()}}new class{constructor(e){let t=arguments.length>1&&void 0!==arguments[1]?arguments[1]:(0,_.ky)(16);c._A?(this.agentIdentifier=t,this.sharedAggregator=new y({agentIdentifier:this.agentIdentifier}),this.features={},this.desiredFeatures=new Set(e.features||[]),this.desiredFeatures.add(m),Object.assign(this,(0,a.j)(this.agentIdentifier,e,e.loaderType||"agent")),this.start()):(0,l.Z)("Failed to initial the agent. Could not determine the runtime environment.")}get config(){return{info:(0,t.C5)(this.agentIdentifier),init:(0,t.P_)(this.agentIdentifier),loader_config:(0,t.DL)(this.agentIdentifier),runtime:(0,t.OP)(this.agentIdentifier)}}start(){const t="features";try{const r=n(this.agentIdentifier),i=[...this.desiredFeatures];i.sort(((t,r)=>e.p[t.featureName]-e.p[r.featureName])),i.forEach((t=>{if(r[t.featureName]||t.featureName===e.D.pageViewEvent){const n=function(t){switch(t){case e.D.ajax:return[e.D.jserrors];case e.D.sessionTrace:return[e.D.ajax,e.D.pageViewEvent];case e.D.sessionReplay:return[e.D.sessionTrace];case e.D.pageViewTiming:return[e.D.pageViewEvent];default:return[]}}(t.featureName);n.every((e=>r[e]))||(0,l.Z)("".concat(t.featureName," is enabled but one or more dependent features has been disabled (").concat((0,D.P)(n),"). This may cause unintended consequences or missing data...")),this.features[t.featureName]=new t(this.agentIdentifier,this.sharedAggregator)}})),(0,T.Qy)(this.agentIdentifier,this.features,t)}catch(e){(0,l.Z)("Failed to initialize all enabled instrument classes (agent aborted) -",e);for(const e in this.features)this.features[e].abortHandler?.();const r=(0,T.fP)();return delete r.initializedAgents[this.agentIdentifier]?.api,delete r.initializedAgents[this.agentIdentifier]?.[t],delete this.sharedAggregator,r.ee?.abort(),delete r.ee?.get(this.agentIdentifier),!1}}}({features:[J,m,S,class extends h{static featureName=oe;constructor(t,r){if(super(t,r,oe,!(arguments.length>2&&void 0!==arguments[2])||arguments[2]),!c.il)return;const n=this.ee;let i;(0,k.QU)(n),this.eventsEE=(0,k.em)(n),this.eventsEE.on(se,(function(e,t){this.bstStart=(0,p.z)()})),this.eventsEE.on(ae,(function(t,r){(0,s.p)("bst",[t[0],r,this.bstStart,(0,p.z)()],void 0,e.D.sessionTrace,n)})),n.on(ce+ne,(function(e){this.time=(0,p.z)(),this.startPath=location.pathname+location.hash})),n.on(ce+ie,(function(t){(0,s.p)("bstHist",[location.pathname+location.hash,this.startPath,this.time],void 0,e.D.sessionTrace,n)}));try{i=new PerformanceObserver((t=>{const r=t.getEntries();(0,s.p)(te,[r],void 0,e.D.sessionTrace,n)})),i.observe({type:re,buffered:!0})}catch(e){}this.importAggregator({resourceObserver:i})}},C,xe,B,class extends h{static featureName=de;constructor(e,r){if(super(e,r,de,!(arguments.length>2&&void 0!==arguments[2])||arguments[2]),!c.il)return;if(!(0,t.OP)(e).xhrWrappable)return;try{this.removeOnAbort=new AbortController}catch(e){}let n,i=0;const o=this.ee.get("tracer"),a=(0,k._L)(this.ee),s=(0,k.Lg)(this.ee),u=(0,k.BV)(this.ee),d=(0,k.Kf)(this.ee),f=this.ee.get("events"),l=(0,k.u5)(this.ee),h=(0,k.QU)(this.ee),g=(0,k.Gm)(this.ee);function m(e,t){h.emit("newURL",[""+window.location,t])}function v(){i++,n=window.location.hash,this[ve]=(0,p.z)()}function b(){i--,window.location.hash!==n&&m(0,!0);var e=(0,p.z)();this[pe]=~~this[pe]+e-this[ve],this[ye]=e}function y(e,t){e.on(t,(function(){this[t]=(0,p.z)()}))}this.ee.on(ve,v),s.on(be,v),a.on(be,v),this.ee.on(ye,b),s.on(ge,b),a.on(ge,b),this.ee.buffer([ve,ye,"xhr-resolved"],this.featureName),f.buffer([ve],this.featureName),u.buffer(["setTimeout"+le,"clearTimeout"+fe,ve],this.featureName),d.buffer([ve,"new-xhr","send-xhr"+fe],this.featureName),l.buffer([me+fe,me+"-done",me+he+fe,me+he+le],this.featureName),h.buffer(["newURL"],this.featureName),g.buffer([ve],this.featureName),s.buffer(["propagate",be,ge,"executor-err","resolve"+fe],this.featureName),o.buffer([ve,"no-"+ve],this.featureName),a.buffer(["new-jsonp","cb-start","jsonp-error","jsonp-end"],this.featureName),y(l,me+fe),y(l,me+"-done"),y(a,"new-jsonp"),y(a,"jsonp-end"),y(a,"cb-start"),h.on("pushState-end",m),h.on("replaceState-end",m),window.addEventListener("hashchange",m,(0,O.m$)(!0,this.removeOnAbort?.signal)),window.addEventListener("load",m,(0,O.m$)(!0,this.removeOnAbort?.signal)),window.addEventListener("popstate",(function(){m(0,i>1)}),(0,O.m$)(!0,this.removeOnAbort?.signal)),this.abortHandler=this.#e,this.importAggregator()}#e(){this.removeOnAbort?.abort(),this.abortHandler=void 0}}],loaderType:"spa"})})(),window.NRBA=o})(); const cookieDomain = window.location.hostname; const tld = buildTLD(); function buildTLD() { const domainParts = cookieDomain.split('.'); while (domainParts.length > 2) { domainParts.shift(); } return domainParts.join('.'); } function deleteCookie(cookieName) { if (!cookieName) { return; } const cookiePath = (cookieName.startsWith('retraction_warning_') || cookieName.startsWith('version_warning_')) ? '/articles/' + cookieName : '/'; // Yes, these three slightly different ways to try and remove cookies are necessary document.cookie = cookieName + '=; path=' + cookiePath + '; domain=' + cookieDomain + '; expires=Thu, 01 Jan 1970 00:00:01 GMT;'; document.cookie = cookieName + '=; path=' + cookiePath + '; domain=.' + tld + '; expires=Thu, 01 Jan 1970 00:00:01 GMT;'; document.cookie = cookieName + '=; path=' + cookiePath + '; expires=Thu, 01 Jan 1970 00:00:01 GMT;'; } function deleteGroupCookies(group) { if (!group) { return; } const domainData = OneTrust.GetDomainData(), cookies = domainData.Groups.filter(cookieGroup => cookieGroup.OptanonGroupId === group)[0].Cookies; cookies.forEach(cookie => deleteCookie(cookie.Name)); } function OptanonWrapper() { const cookieConsentGroups = []; for (group of OneTrust.GetDomainData().Groups) { cookieConsentGroups.push(group.OptanonGroupId); } OneTrust.OnConsentChanged(function(e) { const cookieConsentActiveGroups = OnetrustActiveGroups.split(',').filter(activeGroup => activeGroup); cookieConsentGroups.forEach(group => { if (!cookieConsentActiveGroups.includes(group)) { deleteGroupCookies(group); }; }); }); } window.jQuery || document.write(' ') CKEDITOR_BASEPATH='https://hrbopenresearch.org/js/vendor/ckeditor/' window.reactTheme = 'HRB'; window.MathJax = { CommonHTML: { linebreaks: { automatic: true } }, 'HTML-CSS': { linebreaks: { automatic: true } }, SVG: { linebreaks: { automatic: true } }, AuthorInit: function() { MathJax.Hub.Register.MessageHook('End Process', function () { let timeout = false; // holder for timeout id const delay = 250; // delay after event is "complete" to run callback const reflowMath = function() { const dispFormulas = document.querySelectorAll('.disp-formula.panel'); if (!dispFormulas) { return; } for (const dispFormula of dispFormulas) { const child = dispFormula.querySelector('.MathJax_Preview').nextSibling.firstChild; const isMultiline = MathJax.Hub.getAllJax(dispFormula)[0].root.isMultiline; if (dispFormula.offsetWidth < child.offsetWidth || isMultiline) { MathJax.Hub.Queue(['Rerender', MathJax.Hub, dispFormula]); } } }; window.addEventListener('resize', function() { clearTimeout(timeout); // clear the timeout timeout = setTimeout(reflowMath, delay); // start timing for event "completion" }); }); }, }; if (window.location.hash == '#_=_'){ window.location = window.location.href.split('#')[0] } !function(f,b,e,v,n,t,s){if(f.fbq)return;n=f.fbq=function() {n.callMethod? n.callMethod.apply(n,arguments):n.queue.push(arguments)} ;if(!f._fbq)f._fbq=n; n.push=n;n.loaded=!0;n.version='2.0';n.queue=[];t=b.createElement(e);t.async=!0; t.src=v;s=b.getElementsByTagName(e)[0];s.parentNode.insertBefore(t,s)}(window, document,'script','https://connect.facebook.net/en_US/fbevents.js'); fbq('init', '1641728616063202'); fbq('track', "PixelInitialized", {}); Skip to content HRB Open Research file_upload Submit your research search clear search menu close clear Search Browse Gateways & Collections How to Publish Submit your Research My Submissions Article Guidelines Article Guidelines (New Versions) Data Guidelines Prepublication Checks Production Process Article Processing Charges Finding Article Reviewers About How it Works For Reviewers National Steering Group Policies Glossary FAQs Contact Blog My Account Submissions Content and Tracking Alerts My Details Sign In file_upload Submit your research { "@context": "https://schema.org", "@type": "ScholarlyArticle", "mainEntityOfPage": { "@type": "WebPage", "@id": "https://hrbopenresearch.org/articles/8-50" }, "headline": "A roadmap towards Ireland’s membership of BBMRI-ERIC", "datePublished": "2025-04-04T16:40:20", "dateModified": "2025-05-29T14:16:32", "author": [ { "@type": "Person", "name": "Amina Arar" }, { "@type": "Person", "name": "Heidi Annuk" }, { "@type": "Person", "name": "Sean O. Hynes" }, { "@type": "Person", "name": "Emma Snapes" }, { "@type": "Person", "name": "Michael Kerin" }, { "@type": "Person", "name": "Sonja Khan" }, { "@type": "Person", "name": "Nicola Miller" } ], "publisher": { "@type": "Organization", "name": "HRB Open Research", "logo": { "@type": "ImageObject", "url": "https://hrbopenresearch.org/img/AMP/HRB_image.png", "height": 566, "width": 60 } }, "image": { "@type": "ImageObject", "url": "https://hrbopenresearch.org/img/AMP/HRB_image.png", "height": 1200, "width": 127 }, "description": " Background BioBANC Symposium has become a key forum for the Irish biobanking community. The third annual event focused on networking and quality, featuring a workshop to explore the role and value of networked biobanking for Ireland. The Director General of BBMRI-ERIC advanced these discussions by addressing an audience of interdisciplinary experts, high-level stakeholders, and policymakers from the Irish biobanking community, as well as representatives from the Health Research Charities Ireland (HRCI), the National Clinical Trials Office (NCTO), the European Clinical Research Infrastructure Network (ECRIN-ERIC) research infrastructure, and the Department of Health. Methods A panel discussion brought together an array of experts from patient advocacy, clinical trials, pharmaceutical industry, government, healthcare policy and BBMRI-ERIC representation to explore the integration of Ireland into the BBMRI-ERIC network. This diverse panel discussed strategies to enhance Ireland’s biobanking capabilities and leverage international collaborations. Themes explored included the benefits, gaps and changes needed if Ireland was to consider membership of BBMRI-ERIC. VEVOX live polling was used to gauge audience views and questions on posed topics, enabling interactive audience participation and capturing real-time feedback to enrich the discussion. Results Substantial benefits that BBMRI-ERIC membership would bring for Ireland were highlighted, including enhanced infrastructure, standardised practices, and greater economic opportunities. Attendees also delved into how Ireland could address current gaps and align its biobanking operations with broader European standards. The discussion identified several critical themes and recommendations to address the need for funding, legislative support, education, public engagement, and strategic planning. Conclusion This article aims to encapsulate the discussions and outcomes of BioBANC Symposium III, focusing on the strategic moves Ireland must consider harnessing the full potential of its biobanking community. It serves not just as a record of proceedings but as a guide for action, urging stakeholders at all levels to collaborate towards a unified goal. " } { "@context": "http://schema.org", "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": "1", "item": { "@id": "https://hrbopenresearch.org/", "name": "Home" } }, { "@type": "ListItem", "position": "2", "item": { "@id": "https://hrbopenresearch.org/browse/articles", "name": "Browse" } }, { "@type": "ListItem", "position": "3", "item": { "@id": "https://hrbopenresearch.org/articles/8-50/v1", "name": "A roadmap towards Ireland’s membership of BBMRI-ERIC " } } ] } Home Browse A roadmap towards Ireland’s membership of BBMRI-ERIC ALL Metrics - Views Downloads Get PDF Get XML Cite How to cite this article Arar A, Annuk H, O. Hynes S et al. A roadmap towards Ireland’s membership of BBMRI-ERIC [version 1; peer review: 1 approved, 3 approved with reservations] . HRB Open Res 2025, 8 :50 ( https://doi.org/10.12688/hrbopenres.14089.1 ) NOTE: If applicable, it is important to ensure the information in square brackets after the title is included in all citations of this article. Close Copy Citation Details Export Export Citation Sciwheel EndNote Ref. Manager Bibtex ProCite Sente EXPORT Select a format first Track Share ▬ ✚ Research Article A roadmap towards Ireland’s membership of BBMRI-ERIC [version 1; peer review: 1 approved, 3 approved with reservations] Amina Arar https://orcid.org/0009-0005-9014-5434 1,2 , Heidi Annuk https://orcid.org/0009-0002-8827-9298 3 , Sean O. Hynes 4,5 , [...] Emma Snapes https://orcid.org/0000-0001-5429-6925 6 , Michael Kerin 3 , Sonja Khan 1,7 * , Nicola Miller https://orcid.org/0000-0002-5416-7047 3 * Amina Arar https://orcid.org/0009-0005-9014-5434 1,2 , Heidi Annuk https://orcid.org/0009-0002-8827-9298 3 , [...] Sean O. Hynes 4,5 , Emma Snapes https://orcid.org/0000-0001-5429-6925 6 , Michael Kerin 3 , Sonja Khan 1,7 * , Nicola Miller https://orcid.org/0000-0002-5416-7047 3 * * Equal contributors PUBLISHED 04 Apr 2025 Author details Author details 1 Institute for Clinical Trials, School of Medicine, University of Galway, Galway, Ireland 2 Lambe Institute for Translational Research, School of Medicine, University of Galway, Galway, Ireland 3 Discipline of Surgery, Lambe Institute for Translational Research, University of Galway, Galway, Ireland 4 Division of Anatomical Pathology, Galway University Hospital, Galway, Ireland 5 Discipline of Pathology, School of Medicine, University of Galway, Galway, Ireland 6 BioConsulting, Cork, Ireland 7 HRB Clinical Research Facility, School of Medicine, University of Galway, Galway, Ireland Amina Arar Roles: Visualization, Writing – Original Draft Preparation, Writing – Review & Editing Heidi Annuk Roles: Writing – Review & Editing Sean O. Hynes Roles: Writing – Review & Editing Emma Snapes Roles: Visualization, Writing – Review & Editing Michael Kerin Roles: Funding Acquisition, Writing – Review & Editing Sonja Khan Roles: Funding Acquisition, Project Administration, Supervision, Visualization, Writing – Original Draft Preparation, Writing – Review & Editing Nicola Miller Roles: Funding Acquisition, Project Administration, Supervision, Visualization, Writing – Original Draft Preparation, Writing – Review & Editing OPEN PEER REVIEW DETAILS REVIEWER STATUS Abstract Background BioBANC Symposium has become a key forum for the Irish biobanking community. The third annual event focused on networking and quality, featuring a workshop to explore the role and value of networked biobanking for Ireland. The Director General of BBMRI-ERIC advanced these discussions by addressing an audience of interdisciplinary experts, high-level stakeholders, and policymakers from the Irish biobanking community, as well as representatives from the Health Research Charities Ireland (HRCI), the National Clinical Trials Office (NCTO), the European Clinical Research Infrastructure Network (ECRIN-ERIC) research infrastructure, and the Department of Health. Methods A panel discussion brought together an array of experts from patient advocacy, clinical trials, pharmaceutical industry, government, healthcare policy and BBMRI-ERIC representation to explore the integration of Ireland into the BBMRI-ERIC network. This diverse panel discussed strategies to enhance Ireland’s biobanking capabilities and leverage international collaborations. Themes explored included the benefits, gaps and changes needed if Ireland was to consider membership of BBMRI-ERIC. VEVOX live polling was used to gauge audience views and questions on posed topics, enabling interactive audience participation and capturing real-time feedback to enrich the discussion. Results Substantial benefits that BBMRI-ERIC membership would bring for Ireland were highlighted, including enhanced infrastructure, standardised practices, and greater economic opportunities. Attendees also delved into how Ireland could address current gaps and align its biobanking operations with broader European standards. The discussion identified several critical themes and recommendations to address the need for funding, legislative support, education, public engagement, and strategic planning. Conclusion This article aims to encapsulate the discussions and outcomes of BioBANC Symposium III, focusing on the strategic moves Ireland must consider harnessing the full potential of its biobanking community. It serves not just as a record of proceedings but as a guide for action, urging stakeholders at all levels to collaborate towards a unified goal. READ ALL READ LESS Keywords Biobanking, BBMRI-ERIC, Clinical Trials, European Research Infrastructure, Biobanking Standardisation, Healthcare Research Integration, Medical Research Networks, Transnational Collaboration Corresponding Author(s) Sonja Khan ( [email protected] ) Close Corresponding author: Sonja Khan Competing interests: No competing interests were disclosed. Grant information: Health Research Board [CES-2024-031]. This work was also supported by the Institute for Clinical Trials, University of Galway; and Genial, National Breast Cancer Research Institute. Amina Arar is supported by the MSc Clinical Research Master’s program and the Institute for Clinical Trials. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. Copyright: © 2025 Arar A et al . This is an open access article distributed under the terms of the Creative Commons Attribution License , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. How to cite: Arar A, Annuk H, O. Hynes S et al. A roadmap towards Ireland’s membership of BBMRI-ERIC [version 1; peer review: 1 approved, 3 approved with reservations] . HRB Open Res 2025, 8 :50 ( https://doi.org/10.12688/hrbopenres.14089.1 ) First published: 04 Apr 2025, 8 :50 ( https://doi.org/10.12688/hrbopenres.14089.1 ) Latest published: 29 May 2025, 8 :50 ( https://doi.org/10.12688/hrbopenres.14089.2 )  There is a newer version of this article available. Suppress this message for one day. Abbreviations BBMRI-ERIC – Biobanking and Biomolecular Resources Research Infrastructure - European Research Infrastructure Consortium BnaG – BioBANC na Gaillimhe CRF – Clinical Research Facility DOH – Department of Health EATRIS-ERIC – European Infrastructure for Translational Medicine - European Research Infrastructure Consortium ECRIN – European Clinical Research Infrastructure Network EHDS – European Health Data Space ERIC – European Research Infrastructure Consortium EU-AMRI – European Union Alliance for Medical Research Infrastructures GDPR – General Data Protection Regulation HRCI – Health Research Charities Ireland HRB – Health Research Board IARC – International Agency for Research on Cancer INAB – Irish National Accreditation Board ISBER – International Society for Biological and Environmental Repositories NBWG – National Biobanking Working Group NCTO – National Clinical Trials Office NREC – National Research Ethics Committees NSAI – National Standards Authority of Ireland PFM – Personalised Functional Medicine PPI – Patient and Public Involvement WHO – World Health Organisation Introduction Biobanks are the cornerstone of biomedical research and healthcare delivery as medicine becomes increasingly personalised. For common complex diseases such as cancer, much of our insight into the causes and treatment of disease has come from analysis of clinical samples. The third annual BioBANC Symposium held at the University of Galway on 6th September 2024, brought together experts and advocates from the Irish biobanking, clinical research, healthcare, industry, and patient advocacy communities. Central to the discussion was Ireland’s membership of Biobanking and Biomolecular Resources Research Infrastructure - European Research Infrastructure Consortium (BBMRI-ERIC), the European Research Infrastructure dedicated to strengthening biomedical research by supporting networked and standardised biobanking practices and policies across Europe in the provision of structured access to quality aligned samples and data 1 . In a welcome address, Professor Michael Kerin, Chair of Surgery, University of Galway, Director of the HSE West and North West Cancer Network and Vice President of the Royal College of Surgeons in Ireland ardently championed the patient’s voice highlighting the challenges of delivering cancer care, recruiting participants for biobanking and clinical trials amid the constraints of the General Data Protection Regulation (GDPR) and the impracticalities of reconsent. He also commented on the importance of biobanking as a key enabler in personalised medicine and advances in cancer care. This prefaced a workshop “Pathway to Ireland joining BBMRI-ERIC” with keynote presentations by Professor Jens Habermann, Director General of BBMRI-ERIC and Dr Eva Ortega-Paino, Secretary General for Research, Ministry of Science, Innovation and Universities, Spain ( Table 1 ). Table 1. Future of Irish Biobanking Community - Roadmap towards BBMRI-ERIC membership panellists. Panellist / Title Representation Affiliation Mr Billy McCann Member Patient and Public Involvement (PPI) National Research Ethics Committee (NREC) Medical Devices National Biobanking Working Group (NBWG) Dr Avril Kennan CEO Patient Advocacy Health Research Charities Ireland (HRCI) Prof Fai Ng Director Clinical Trials Clinical Research Facility (CRF) University College Cork (UCC) National Clinical Trials Office (NCTO) Dr Robert O’Connor Director Clinical Trials (ECRIN) Research Infrastructure HRB-National Clinical Trials Office (NCTO), UCC Ms Orlaith Gavan Country Medical Director Pharmaceutical Industry Pfizer Healthcare, Ireland Dr Eva Ortega-Paino Secretary General Government Representative Ministry of Science, Innovation and Universities, Spain Professor Jens Habermann Director General European Research Infrastructure BBMRI-ERIC In an opening presentation titled “Setting the Scene of Biobanking in Ireland”, Oonagh Ward, Head of Research and Innovation Infrastructures, Health Research Board (HRB) outlined previous Irish biobanking position papers and why biobanking infrastructure in Ireland has failed to date. Reference was made to the HRB’s commitment to biobanking as a key action in the HRB strategy 2021–2025 to: “Take a leading role to convene stakeholders to progress the design, development and implementation of national, shared high-cost research infrastructures, including in the areas of biobanking and genomic research” 2 . A vision towards BBMRI-ERIC membership was signposted using experience from the strategic investment in clinical trials in Ireland to standardise expertise and delivery through membership of the European Clinical Research Infrastructure Network (ECRIN) the European research infrastructure (ERIC) for clinical trials as precedence. Professor Jens Habermann, Director General of BBMRI-ERIC, highlighted the extensive capabilities of the BBMRI-ERIC network in his keynote address, “Connecting Ireland to Europe's Biobanking and Biomolecular Resources Research Infrastructure.” As one of the largest distributed research infrastructures, with its headquarters in Graz, Austria, BBMRI-ERIC represents almost 500 biobanks across 25 Member and Observer countries, including the International Agency for Research on Cancer (IARC)/World Health Organisation (WHO). It offers scientific services for ethical, legal and societal issues, quality management, IT services, biobanking development, and provides central services and functions such as finance and project management, public affairs, and outreach, education and communications. It furthermore operates the world’s largest biobank catalogue – the BBMRI-ERIC Directory. The scale of BBMRI-ERIC’s connectivity to a vast network of partners and EU initiatives illustrates its extensive reach. This network includes the ERIC Forum, which BBMRI-ERIC coordinates, and other European Research Infrastructures in the field of health and life sciences. With a coordinating role in projects relating to EU priorities such as EU Mission on Cancer or further strengthening of Research Infrastructures and ERICs, as well as an important role in other projects, BBMRI-ERIC is contributing its core expertise towards structuring the European Research Area. In this respect, BBMRI-ERIC’s federated access and analysis platform has become a strong asset and reference point for EU initiatives such as the European Health Data Space (EHDS) and EUropean Federation for CAncer IMages (EUCAIM) and serves as an example of the impact of BBMRI-ERIC core expertise on EU health and life science research developments. BBMRI-ERIC’s new 10-Year Roadmap, including its vision, mission and strategic objectives, was outlined, emphasising a One Health approach in biobanking ( Figure 1 ). This One Health concept, driven by WHO, is an integrated unifying approach recognising that the health of humans, animals, plants, and the wider environment are closely linked and inter-dependent. Figure 1. BBMRI-ERIC's 10-Year Roadmap overview. Dr Ortega-Paino’s keynote “Sharing is caring: the case of BBMRI Spain”, outlined Spanish research infrastructure and Spain’s involvement in European research infrastructure programmes. Underscoring Spain’s strategic positioning in research infrastructure and its commitment to advancing biobanking through collaboration, quality assurance and innovation, Spain joined BBMRI-ERIC as an observer in 2021, with active participation in working groups and task forces. BBMRI-ERIC observer status is granted for a maximum period of three years, after which Spain will request full membership from the BBMRI-ERIC Assembly of Members. Dr Ortega-Paino reported the benefits of BBMRI-ERIC membership for Spain’s research landscape, including improved data quality, ethical compliance, and streamlined access to research samples and infrastructure. This membership supported enhanced collaboration and integration with EU research networks. Opening a panel discussion on "Future of Irish Biobanking Community - Roadmap towards BBMRI-ERIC Membership", Dr Sonja Khan, Head of Education at the Institute for Clinical Trials, University of Galway, presented a survey of biobanking practice in Ireland. The study identified 36 biobanks, mostly in Dublin, followed by Galway and Cork, with the majority linked to academic or non-profit institutions and focused on disease-specific research, particularly cancer. The study highlighted infrastructural gaps in the Irish biobanking community, in particular the lack of a national biobanking registry and concluded that a comprehensive biobank registry would enhance transparency and inform government funding 3 . These findings align with the Health Research Charities Ireland (HRCI) November 2023 report recommending a thorough review of Ireland's biobanking landscape 4 . A discussion, exploring Ireland’s potential membership of BBMRI-ERIC followed. Panellists included Mr Billy McCann, a Patient and Public Involvement (PPI) representative and IPPOSI graduate; Dr Avril Kennan, HRCI, Prof Fai Ng, HRB Clinical Research Facility (CRF) UCC, Orlaith Gavan, Pfizer Healthcare Ireland, Dr Robert O’Connor, National Clinical Trials Office (NCTO) Dr Eva Ortega-Paino, Spain and Prof Jens Habermann, BBMRI-ERIC (see Table 1 for full details of speaker affiliations). The discussion was hosted by Emma Snapes, BioConsulting, Cork. Methods Discussions and outcomes from the panel were captured and reproduced with consent from the participants and thematic analysis was conducted to identify key themes related to the benefits, gaps, and strategic imperatives for enhancing Ireland’s biobanking framework. Panel participants and speakers provided consent for their contributions to be included in the study analysis. Questions for the panel were prepared by the BioBANC na Gaillimhe organising committee ahead of the symposium, to guide discussions towards achieving strategic goals. During the discussion, VEVOX live polling was used to gauge audience views and questions on posed topics, enabling interactive audience participation and capturing real-time feedback to enrich the discussion. Responses to the question "What steps can be taken to better map the Irish Biobanking landscape?" were visually summarised in a word cloud ( Figure 2 ), highlighting key themes such as legislation, funding, and public outreach as important in shaping the future of Irish biobanking. Figure 2. Word cloud of responses to 'What steps can be taken to better map the Irish Biobanking landscape?' Results Question 1: What steps can be taken to better map the Irish Biobanking landscape? Dr Eva Ortega-Paino, Secretary General of Spain’s Ministry of Science, Innovation, and Universities, set the stage for the discussion by emphasising the need for foundational education across all stakeholder groups. She argued that education is the starting point for every successful biobanking initiative. According to Dr Ortega-Paino, educating stakeholders as well as the public, is essential for fostering understanding and unity around Ireland’s biobanking goals. Dr Ortega-Paino discussed Spain’s experience in advancing its biobanking capabilities and how it overcame challenges similar to those faced by Ireland by implementing a national education initiative. This initiative successfully aligned the stakeholders with the biobanking mission, building a supportive and active biobanking community across Spain. Prof Jens Habermann, Director General of BBMRI-ERIC, emphasised the importance of an inclusive definition of "biobank" in fostering collaboration among patients, scientists, clinicians, and industry representatives. He commended the Irish Health Research Forum’s efforts to unite stakeholders and establish a shared vision, describing it as a significant milestone for Irish biobanking. According to Prof Habermann, a unified vision is key: engaging all stakeholders will set a foundation to propel Irish biobanking forward with strength and cohesion. This call for stakeholder engagement was echoed by Mr Billy McCann, a PPI Member of the National Biobanking Working Group (NBWG) and the National Research Ethics Committees (NREC) for Medical Devices and an IPPOSI graduate, who spoke about the limited awareness among patients and the public regarding biobanking and its relevance. He recounted his experience learning about biobanking and noted that his peers, although informed about medical research, had little understanding of biobanking’s value. This reflects the need for a more robust public education campaign: “I think a huge job of education needs to be done in the context of the general public.” People want to contribute to research, but they need to better understand how their contributions make a difference. This was further echoed at the National Biobanking Symposium organised by the Biobank Ireland Trust on October 26th 2024. One of the primary discussions centred around the need to better define and map the biobanking landscape in Ireland. It was emphasised that a comprehensive understanding of what constitutes a biobank and where existing resources are located is crucial. This includes recognising the potential of collections that may not traditionally be classified as biobanks, such as those in hospitals, and the importance of educating both the biobanking community and the broader public about these resources. Another significant topic was the alignment with international standards and the potential benefits of increased collaboration. The discussions pointed to the importance of creating flexible yet definitive guidelines that could accommodate a wide range of stakeholders, including patient representatives, clinicians, researchers, and industry professionals. Establishing clear roadmaps and fostering cooperative initiatives were seen as essential steps towards developing a coherent strategy for biobanking in Ireland. Funding and sustainability also emerged as critical themes. The need for more robust funding mechanisms was highlighted, with suggestions that biobanking should be integrated into the healthcare system's infrastructure, akin to essential diagnostic tools. This would ensure long-term sustainability and efficacy, moving beyond the limitations of short-term research grants. Question 2: What are the benefits of joining BBMRI-ERIC—why is it important? The discussion on the benefits of Ireland joining BBMRI-ERIC highlighted the strategic and collaborative advantages of such a step. The dialogue emphasised the necessity of transcending isolated efforts in biobanking within Ireland and leveraging a broader European network. Prof Jens Habermann emphasised the need for a collaborative approach in biobanking, stating, “It's a very dynamic field, and you need to involve all stakeholders, including patient representatives, scientists, clinicians, industry, and the public.” He strongly advocated against operational isolation by highlighting, “we cannot continue working in silos.” Prof Habermann argued that joining BBMRI-ERIC would seamlessly integrate Ireland into a global network characterised by standardised, regulated, and collaborative practices. Such membership would not only unlock the full potential of Ireland’s biobanks but also significantly support both public and private sectors in building a healthcare system equipped to address the nation’s complex health challenges. The discussions also touched upon the need for standardisation and efficiency in biobanking processes, which could be significantly enhanced through Ireland’s membership of BBMRI-ERIC. This would not only facilitate improved research outcomes but also ensure that Irish biobanking practices are aligned with international best practices and regulatory standards. Panellists discussed the dual benefits of joining BBMRI-ERIC from both a strategic and ethical standpoint. By integrating into this network, Ireland would not only improve its biobanking infrastructure but also contribute to and benefit from collective European efforts in medical research and healthcare advancements. This cooperation is seen as crucial for facing the rapid pace of change in global healthcare needs and research demands. Dr Robert O'Connor added a critical perspective on the operational challenges and regulatory aspects of biobanking. He argued for the inclusion of Ireland in BBMRI-ERIC from an infrastructural and economic perspective. He mentioned that as European citizens, Irish researchers and institutions have much to gain from and contribute to this collective endeavour. He discussed the importance of standardisation, using his experiences to illustrate how variations in medical testing across hospitals could affect patient care more significantly than the conditions being tested. Question 3: What gaps need to be addressed to join, and how should they be addressed? In addressing the third question posed to the panel about the steps Ireland needs to take to join BBMRI-ERIC, the discussion largely highlighted Ireland's readiness and strong potential for aligning with European biobanking standards. Prof Jens Habermann, Director General of BBMRI-ERIC, underscored that no significant barriers exist to delay Ireland’s inclusion, advocating for swift action: “There is no gap that needs to be overcome first. Join - we will do the rest together. Ireland has all it takes to become a member.” Other panellists pointed out specific areas needing attention, such as the lack of a comprehensive ethical framework specific to biobanking in Ireland. This gap is seen as a barrier to standardising biobanking practices to meet international norms. Another highlighted gap was the perceived lack of political awareness and will. This absence of biobanking on the political agenda could suggest politicians are not pressured to act because they are not informed about the importance of biobanking. The Secretary General for Research Ministry of Science Innovation and Universities of Spain, Dr Eva Ortega-Paino, echoed this sentiment stressing the need for proactive engagement with politicians to raise awareness and foster legislative support. The fragmentation of the Irish biobanking community has been recognised as a significant obstacle to realising the full potential of biobanking as a critical enabler of research. This fragmentation hinders the HRB’s ability to appreciate the integral role biobanking plays in the research they fund. Addressing this gap aligns with Objective 4 of the HRB Strategy 2021–2025, which emphasises the creation of a thriving research environment 5 . Question 4: Are there any parallels with clinical trials—European Clinical Research Infrastructure Network (ECRIN)? If so, what can the biobanking community learn from clinical trials and vice versa? The panel discussion delved into the parallels between clinical trials network ECRIN 6 and biobanking, particularly focusing on what the biobanking community could learn from the success and integration of clinical trials into a European framework. In 2022, the European Clinical Research Infrastructure Network (ECRIN) partnered with the European Research Infrastructure for Biobanking and Biomolecular Resources (BBMRI-ERIC) and the European Infrastructure for Translational Medicine (EATRIS-ERIC) to establish the European Alliance of Medical Research Infrastructures (EU-AMRI) 7 . This alliance was formed to deliver complementary services to researchers in the field of biomedical sciences, with a focus on advancing personalised medicine and the development of new therapeutic approaches. The EU-AMRI was officially launched on April 5, 2022, in Brussels. During the launch event, the directors of the three infrastructures outlined the strategic goals of the alliance and the significance of collaborative efforts in expediting patient access to innovative treatments 8 . Dr Robert O'Connor/and other panellists discussed the parallels between ECRIN and BBMRI-ERIC, considering the former's 13-member state membership and how Ireland’s HRB provides funding through the Department of Health (DoH) for ECRIN membership. He noted the different nature of BBMRI-ERIC, which focuses more on biobanking compared to ECRIN’s investigator-led trials. Dr Robert O’Connor stressed the importance of not waiting for perfect conditions to join BBMRI-ERIC, advocating for concurrent actions in addressing legislative gaps and improving biobanking processes to maximise the benefits of membership. Similarly, Ms Oonagh Ward highlighted the similarities in complexity between the ECRIN and BBMRI-ERIC landscapes but pointed out that ECRIN had a strategic plan and strong government support that facilitated its success. She emphasised the need for a similar strategic approach for biobanking in Ireland to effectively join and benefit from BBMRI-ERIC. The importance of standardisation across biobanking was underscored, noting that aligning with European standards can significantly enhance credibility and public trust in biobanking practices. Such standardisation not only assures patients donating samples for research of the integrity and safety of the processes but also paves the way for international collaborations that are vital for advancing personalised medicine. Orlaith Gavan, Country Medical Director at Pfizer Healthcare Ireland, emphasised the pharmaceutical sector's strong backing for advancing biobanking infrastructure. Noting that the shift toward personalised treatments depends on robust biobanking systems, which enable tailored therapeutic development, Orlaith Gavan also pointed out that a well-supported biobanking infrastructure could significantly boost Ireland's competitiveness in attracting novel clinical trials, a key aspect of drug development and evidence-based healthcare. She underscored biobanking’s vital role in pharmaceutical R&D, positioning it as a cornerstone for driving innovation in medical solutions. Prof Fai Ng, Director at the HRB CRF UCC, shared valuable insights into the structure and funding of biobanking. Drawing on his UK experience, he proposed strategies to strengthen biobanking initiatives in Ireland. He emphasised the importance of national and regional support, suggesting that Research Ireland (formerly Science Foundation Ireland) could adopt a role akin to that of the UK’s Medical Research Council in advancing biobanking infrastructure. Prof Ng also emphasised the need to establish a national registry for biobanks, facilitating streamlining access and increased utilisation, thereby enhancing their value as a shared resource. His recommendations underscore the importance of adapting successful international strategies to bolster Irish biobanking for both national and global research efforts. Discussion The panel emphasised the need for a strategic approach to overcome legislative and procedural challenges in Irish biobanking. Aligning with European standards and pursuing BBMRI-ERIC membership were discussed as key steps. These measures would enhance research capabilities and enable more effective, personalised healthcare solutions. A vision for a diverse and inclusive Irish biobanking network was also highlighted, stressing the importance of representing all population segments to ensure comprehensive and impactful health research in a multicultural society. The panel advocated for immediate and proactive steps towards integrating into the European biobanking framework through BBMRI-ERIC. This approach is a vital step toward standardisation, collaboration, and advancing Irish healthcare, representing a commitment to patients, researchers, and industry partners. The panel’s consensus was clear: Ireland’s healthcare and research infrastructures would benefit greatly from the integration, standardisation, and collaborative opportunities that BBMRI-ERIC membership provides. For Ireland, joining this network is not merely an opportunity; it is an obligation to the patients, researchers, and industry partners who are committed to advancing Irish healthcare. Joining BBMRI-ERIC is a decisive step toward fulfilling this commitment, and Ireland is poised to make that leap, equipped with the support of its dedicated stakeholders and a unified vision ( Figure 3 ). Figure 3. Key takeaways from the BnaG panel discussion. Audience polling revealed strong support for Ireland joining BBMRI-ERIC, with 100% of respondents in favour and 75% willing to provide contact details for further engagement. Stakeholders’ primary interest lay in biobanking’s future, with 60% from academia, 14% from government agencies, and 7% each from hospitals and charitable organisations. This highlights the interdisciplinary nature of biobanking, uniting healthcare, regulatory, and non-profit sectors. The unanimous support underscores the community’s commitment to strengthening Ireland’s biobanking infrastructure and its international research role. This engaging exchange reinforced a shared commitment among stakeholders to strengthen Ireland’s biobanking capabilities and prioritise membership in BBMRI-ERIC, a pivotal step in fostering international collaboration and advancing healthcare outcomes. Joining BBMRI-ERIC is seen as essential for aligning Ireland’s biobanking infrastructure with global standards, improving patient care, and unlocking broader research and economic opportunities. The session on "Quality Matters" highlighted the importance of standards and best practices in biobanking. Linda Hendy from the National Standards Authority of Ireland (NSAI) and William Clarke from the Irish National Accreditation Board (INAB) emphasised the critical roles of standardisation, accreditation, and compliance in ensuring the credibility of biobanking operations and fostering international collaboration. Dr Nicola Miller and Dr Oliver Carroll (University of Galway) outlined International Society for Biological and Environmental Repositories (ISBER) Best Practices and the value of proficiency testing in maintaining material fitness and enhancing performance. Jack O'Grady (My Green Lab) discussed promoting environmental sustainability in laboratory operations. Dr Richard Flavin (Trinity College Dublin) showcased Biobank Ireland Trust’s efforts in providing high-quality tissue samples for cancer research and fostering a federated biobank network, advocating for patient and public involvement (PPI) and ethical governance. Prof Seán O. Hynes (University of Galway/University Hospital Galway) concluded the session by reaffirming the commitment to advancing research, improving healthcare outcomes, and solidifying Ireland’s role in the global biobanking landscape. Conclusion BioBANC Symposium III demonstrated the strong support for networked biobanking and BBMRI-ERIC membership from the stakeholders in Ireland’s biobanking community, patient advocacy groups, and the pharmaceutical industry. The infrastructural support is crucial for strengthening the foundation of biobanking in Ireland and enhancing its impact on global biobanking practices. Furthermore, there is a critical need to address human capital gaps to facilitate the activation of BBMRI-ERIC membership and ensure preparedness upon approval. Membership in BBMRI-ERIC would align Ireland with leading European research infrastructures, enhancing its research capabilities and fostering international collaborations. It would also promote higher standards and economic growth through improved research infrastructure. The discussions and strategies outlined at the symposium provide a roadmap for advancing Ireland’s biobanking capabilities to effectively meet current and future health research challenges. “ BioBANC Symposium has become an essential platform for bringing together the specialised community of Irish biobanking professionals. As biobanks continue to evolve, they are playing an increasingly critical role in advancing healthcare and addressing some of the world’s most pressing health challenges. This evolution is bringing changes in the relationship between biobanks and the biological samples and data they are entrusted to preserve by patients and participants. The Irish biobanking community is advocating that these changes are best navigated in alignment with our European partners through membership of BBMRI-ERIC. Láidir le chéile”. Dr Nicola Miller, Dr Sonja Khan – BioBANC na Gaillimhe “BBMRI-ERIC membership significantly enhances member states’ health research capabilities by providing access to resources of almost 500 biobanks, while ensuring adherence to biobanking standards and ethical, legal and societal aspects. Ireland's membership would align with the BBMRI-ERIC 10-Year Roadmap "Biobanking for a Healthier World," which aims to unlock the potential of biobanking and biomolecular resources to inspire the best research for the benefit of patients, the public, and the planet. We therefore hope for Ireland to join our community.” Prof Jens K. Habermann – Director General, BBMRI-ERIC “A huge job of education needs to be done in the context of the general public. People want to contribute to research, but they need to better understand how their contributions make a difference” Mr Billy McCann – PPI Member NBWG, NREC for Medical Devices, IPPOSI graduate. "We simply owe it to our patients. We are not doing anywhere close to enough. For patients, when they attend our hospital and social care services, and if research is embedded, that could be completely different. Let's just get on with it." Dr Avril Kennan – CEO Health Research Charities Ireland (HRCI) “Pfizer invests a significant amount in Ireland and recognises the importance of biobanking, which is why it is built into all clinical trials. To maintain Ireland’s position in oncology, we simply must improve, if we are to continue to position Ireland as world class”. Orlaith Gavan – Chief Medical Officer, Pfizer Healthcare, Ireland "We need to involve all stakeholders - patient representatives, scientists, clinicians, industry, and the public - to leverage existing expertise, tools, and innovation, creating new synergies. We must move beyond working in silos to fully leverage resources and expertise. This is crucial as we face dramatic global challenges; we cannot afford to waste these resources." Prof Jens K. Habermann – Director General, BBMRI-ERIC “We in University of Galway are fortunate to have our translational research facility and biobank co-located with the main teaching hospital and cancer centre in the West and Northwest of Ireland. As Director of the regional Cancer Network, biobanks and multidisciplinary teams working across hospital and academia are essential to enabling patient focused research. I am delighted to see this BioBANC Symposium taking place, encouraging collaboration and knowledge exchange between researchers, clinicians, educators, and members of the public.” Prof Michael Kerin – Chair of Surgery, University of Galway (formerly NUI Galway), Director of the HSE West and North West Cancer Network and Vice President of the Royal College of Surgeons in Ireland. Ethics and consent The manuscript reports on a panel discussion held during the BioBANC Symposium, which featured invited experts discussing publicly available information and their professional opinions. As this was a symposium rather than a study involving the systematic collection of data from human subjects, no formal ethical approval was required. The format of the panel discussion did not involve interventions with or treatments of human subjects as defined under the Declaration of Helsinki, nor did it include any personal or sensitive data subject to ethical oversight. Consent for including the names and contributions of the panellists was obtained. All panellists were contacted via email and agreed to have their discussions and professional opinions included in the report. Data availability Underlying data Data from VEVOX polling conducted during the BioBANC Symposium, includes aggregated stakeholder opinions on biobanking and BBMRI-ERIC membership, is used in the discussion to contextualise community engagement and support. To ensure participant privacy and comply with data protection standards, the raw polling data is not publicly accessible. However, summary data and key insights are incorporated directly into the manuscript text. Additionally, a word cloud ( Figure 2 ) generated from VEVOX polling results is included to visually represent the support for enhancing Ireland's biobanking infrastructure. Acknowledgement Saravana Pandian Boominathan, Clinical Research Associate, University of Galway. Robert O’Connor, Director of HRB-National Clinical Trials Office (NCTO), UCC. Anne Costello, Project Officer - Health Research Board. Johanna Kostenzer, Senior Public Affairs Specialist BBMRI-ERIC. Faculty Opinions recommended References 1. European research infrastructures. European Commission, 2020; [cited 2024 Dec 9]. Reference Source 2. HRB | Health Research Board: Strategy 2021 – 2025. [cited 2024 Dec 9]. Reference Source 3. Boominathan SP: Biobank landscape across island of Ireland. Review of the current biobanks in Ireland and what core systems they are applying. [dissertation]. Galway (Ireland): University of Galway, 2024. 4. Irish Health Research Forum: Biobanking in Ireland: moving forward. Recommendations and event report. Dublin: Health Research Charities Ireland, Nov 16, 2023. Reference Source 5. HRB | Health Research Board: Strategy 2021 – 2025. [cited 2025 Jan 8]. Reference Source 6. Ecrin: Facilitating European clinical research. [cited 2024 Dec 16]. Reference Source 7. ECRIn partners. Ecrin. [cited 2024 Dec 16]. Reference Source 8. EU-AMRI formal launch on 5 April. BBMRI-ERIC. [cited 2024 Dec 11]. Reference Source Comments on this article Comments (0) Version 2 VERSION 2 PUBLISHED 04 Apr 2025 ADD YOUR COMMENT Comment Author details Author details 1 Institute for Clinical Trials, School of Medicine, University of Galway, Galway, Ireland 2 Lambe Institute for Translational Research, School of Medicine, University of Galway, Galway, Ireland 3 Discipline of Surgery, Lambe Institute for Translational Research, University of Galway, Galway, Ireland 4 Division of Anatomical Pathology, Galway University Hospital, Galway, Ireland 5 Discipline of Pathology, School of Medicine, University of Galway, Galway, Ireland 6 BioConsulting, Cork, Ireland 7 HRB Clinical Research Facility, School of Medicine, University of Galway, Galway, Ireland Amina Arar Roles: Visualization, Writing – Original Draft Preparation, Writing – Review & Editing Heidi Annuk Roles: Writing – Review & Editing Sean O. Hynes Roles: Writing – Review & Editing Emma Snapes Roles: Visualization, Writing – Review & Editing Michael Kerin Roles: Funding Acquisition, Writing – Review & Editing Sonja Khan Roles: Funding Acquisition, Project Administration, Supervision, Visualization, Writing – Original Draft Preparation, Writing – Review & Editing Nicola Miller Roles: Funding Acquisition, Project Administration, Supervision, Visualization, Writing – Original Draft Preparation, Writing – Review & Editing Competing interests No competing interests were disclosed. Grant information Health Research Board [CES-2024-031]. This work was also supported by the Institute for Clinical Trials, University of Galway; and Genial, National Breast Cancer Research Institute. Amina Arar is supported by the MSc Clinical Research Master’s program and the Institute for Clinical Trials. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. Article Versions (2) version 2 Revised Published: 29 May 2025, 8:50 https://doi.org/10.12688/hrbopenres.14089.2 version 1 Published: 04 Apr 2025, 8:50 https://doi.org/10.12688/hrbopenres.14089.1 Copyright © 2025 Arar A et al . This is an open access article distributed under the terms of the Creative Commons Attribution License , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Download Export To Sciwheel Bibtex EndNote ProCite Ref. Manager (RIS) Sente metrics VIEWS $counts.viewCount downloads Citations open_in_new 0 open_in_new 0 open_in_new SEE MORE DETAILS CITE how to cite this article Arar A, Annuk H, O. Hynes S et al. A roadmap towards Ireland’s membership of BBMRI-ERIC [version 1; peer review: 1 approved, 3 approved with reservations] . HRB Open Res 2025, 8 :50 ( https://doi.org/10.12688/hrbopenres.14089.1 ) NOTE: If applicable, it is important to ensure the information in square brackets after the title is included in all citations of this article. COPY CITATION DETAILS track receive updates on this article Track an article to receive email alerts on any updates to this article. TRACK THIS ARTICLE Share Open Peer Review Current Reviewer Status: ? Key to Reviewer Statuses VIEW HIDE Approved The paper is scientifically sound in its current form and only minor, if any, improvements are suggested Approved with reservations A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. Not approved Fundamental flaws in the paper seriously undermine the findings and conclusions Version 1 VERSION 1 PUBLISHED 04 Apr 2025 Views 0 Cite How to cite this report: Wutte A. Reviewer Report For: A roadmap towards Ireland’s membership of BBMRI-ERIC [version 1; peer review: 1 approved, 3 approved with reservations] . HRB Open Res 2025, 8 :50 ( https://doi.org/10.21956/hrbopenres.15478.r46682 ) The direct URL for this report is: https://hrbopenresearch.org/articles/8-50/v1#referee-response-46682 NOTE: it is important to ensure the information in square brackets after the title is included in this citation. Close Copy Citation Details Reviewer Report 30 Apr 2025 Andrea Wutte , BBMRI-ERIC, Korneuburg, Austria Approved with Reservations VIEWS 0 https://doi.org/10.21956/hrbopenres.15478.r46682 Notes to the authors: The manuscript is well written and gives the reader an good overview on the discussion during the BioBANC Symposium. Notes to: 1. Is the work clearly ... Continue reading READ ALL Notes to the authors: The manuscript is well written and gives the reader an good overview on the discussion during the BioBANC Symposium. Notes to: 1. Is the work clearly and accurately presented and does it cite the current literature? Reference #1 directs to a general EU Commission page on research infrastructures, while the text specifically mentions BBMRI-ERIC. This should be clarified, and a direct link to the BBMRI-ERIC website would be helpful. Reference #3 cites a dissertation referenced by Dr. Sonja Kahn. Is this dissertation publicly accessible? If so, please provide a direct link. References #2 and #5 point to the same source—are there any differences between them? If not, consider consolidating. Reference #7 should link to EU-AMRI, as per the text. The correct link is: https://eu-amri.org . Note to 2. If applicable, is the statistical analysis and its interpretation appropriate? In the discussion, the authors should provide reference figures (e.g., total number of audience polling = 100%) to clarify what the presented percentages represent. To reinforce the point raised in Question 1—“better define and map the biobanking landscape in Ireland”—the authors could explain how the audience’s affiliations (e.g., academia, hospitals) reflect the broader national landscape. Including national-level benchmarks would help contextualize the data in a bigger picture. For example, how representative is the symposium audience of the wider group of stakeholders who could benefit from initiatives like BioBANC hence would benefit from joining BBMRI-ERIC? Is the work clearly and accurately presented and does it cite the current literature? Partly Is the study design appropriate and is the work technically sound? Yes Are sufficient details of methods and analysis provided to allow replication by others? Yes If applicable, is the statistical analysis and its interpretation appropriate? Partly Are all the source data underlying the results available to ensure full reproducibility? Yes Are the conclusions drawn adequately supported by the results? Yes Competing Interests: No competing interests were disclosed. Reviewer Expertise: Biologist, certified Quality Manager, certified Lead auditor and technical assessor for Accreditation bodies (eg. Biobanking and Pre-analytical standards) . 10 y Experience in Biobanking and building a European biobank network. I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above. Close READ LESS CITE CITE HOW TO CITE THIS REPORT Wutte A. Reviewer Report For: A roadmap towards Ireland’s membership of BBMRI-ERIC [version 1; peer review: 1 approved, 3 approved with reservations] . HRB Open Res 2025, 8 :50 ( https://doi.org/10.21956/hrbopenres.15478.r46682 ) The direct URL for this report is: https://hrbopenresearch.org/articles/8-50/v1#referee-response-46682 NOTE: it is important to ensure the information in square brackets after the title is included in all citations of this article. COPY CITATION DETAILS Report a concern Respond or Comment COMMENT ON THIS REPORT Views 0 Cite How to cite this report: Capello D. Reviewer Report For: A roadmap towards Ireland’s membership of BBMRI-ERIC [version 1; peer review: 1 approved, 3 approved with reservations] . HRB Open Res 2025, 8 :50 ( https://doi.org/10.21956/hrbopenres.15478.r46679 ) The direct URL for this report is: https://hrbopenresearch.org/articles/8-50/v1#referee-response-46679 NOTE: it is important to ensure the information in square brackets after the title is included in this citation. Close Copy Citation Details Reviewer Report 28 Apr 2025 Daniela Capello , Department of Translational Medicine, University of Eastern Piedmont, Novara, Italy Approved with Reservations VIEWS 0 https://doi.org/10.21956/hrbopenres.15478.r46679 Overall, this is a well-written paper that highlights the scientific, ethical, and societal benefits of increasing awareness about biobanking and the opportunities that BBMRI-ERIC membership offers to enhance the quality and coherence of national efforts. In particular, the article underlines ... Continue reading READ ALL Overall, this is a well-written paper that highlights the scientific, ethical, and societal benefits of increasing awareness about biobanking and the opportunities that BBMRI-ERIC membership offers to enhance the quality and coherence of national efforts. In particular, the article underlines the potential for growth in scientific excellence, ethical governance, and community engagement. At the same time, it thoughtfully addresses key challenges, such as the limited political awareness, the fragmentation of the current biobanking landscape, and the importance of fostering greater public and patient understanding of their essential role in advancing research, primarily through biobanking. These considerations are relevant not only for countries like Ireland, which is in the process of joining BBMRI-ERIC, but also for member countries, which must continue to nurture awareness and uphold best practices to maximize the value of biobanking infrastructures. Here are a few suggestions for improvement: - The manuscript refers throughout to the “BioBANC Symposium” , but the term BioBANC itself is not clearly defined. It would be helpful to explain early in the text what BioBANC stands for—whether it is a formal initiative, a project, or a recurring event—and to clarify its role within the Irish biobanking community. - The abbreviation BnaG is listed among the abbreviations, but it is not used anywhere in the body of the manuscript. - The acronyms HSE and IPPOSI are used in the text but are not spelled out on first use, nor are they listed among the abbreviations. For clarity, particularly for international readers, please consider spelling out HSE and IPPOSI when they are first mentioned and including them in the list of acronyms. - VEVOX polling is mentioned multiple times and appears to have provided valuable real-time feedback during the symposium. However, the manuscript would benefit from a brief explanation of what VEVOX is, particularly for readers unfamiliar with the tool. It would also be helpful to include additional methodological details, for example, the number and type of questions posed (e.g., multiple-choice, free-text), the overall number of participants who responded, and how the responses were analyzed or summarized. This would provide helpful context for interpreting the visual elements (e.g., the word cloud) and the polling insights discussed in the results and discussion sections. Additional suggestions for improvement: The "Quality Matters" session in the Discussion section is briefly summarised through a list of names and contributions, but it would benefit from better contextualisation. Clarifying the objectives of this session, its relation to the overall symposium theme, and how it connects to the roadmap towards BBMRI-ERIC membership would help the reader better understand its relevance and impact. The brief reference to the Biobank Ireland Trust could also be more clearly linked to the rest of the article. Specifically, it would be helpful to clarify Biobank Ireland Trust's relationship to BioBANC na Gaillimhe or the national biobanking framework and whether it is part of the same strategic network or represents a complementary initiative. This would provide readers with a more cohesive understanding of the national landscape. Is the work clearly and accurately presented and does it cite the current literature? Yes Is the study design appropriate and is the work technically sound? Yes Are sufficient details of methods and analysis provided to allow replication by others? Yes If applicable, is the statistical analysis and its interpretation appropriate? Not applicable Are all the source data underlying the results available to ensure full reproducibility? No source data required Are the conclusions drawn adequately supported by the results? Yes Competing Interests: No competing interests were disclosed. Reviewer Expertise: Biobanking quality and sustainability, technical and ELSI aspects, public and patient engagement, population-based studies, biomarker discovery I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above. Close READ LESS CITE CITE HOW TO CITE THIS REPORT Capello D. Reviewer Report For: A roadmap towards Ireland’s membership of BBMRI-ERIC [version 1; peer review: 1 approved, 3 approved with reservations] . HRB Open Res 2025, 8 :50 ( https://doi.org/10.21956/hrbopenres.15478.r46679 ) The direct URL for this report is: https://hrbopenresearch.org/articles/8-50/v1#referee-response-46679 NOTE: it is important to ensure the information in square brackets after the title is included in all citations of this article. COPY CITATION DETAILS Report a concern Author Response 03 Jun 2025 Amina Arar , Institute for Clinical Trials, School of Medicine, University of Galway, Galway, Ireland 03 Jun 2025 Author Response We thank the reviewer for their thoughtful and encouraging feedback. We appreciate the valuable suggestions provided to improve clarity and coherence. We have addressed each of the points below: ... Continue reading We thank the reviewer for their thoughtful and encouraging feedback. We appreciate the valuable suggestions provided to improve clarity and coherence. We have addressed each of the points below: R1 and R2. To provide greater clarity, we have added a sentence early in the Introduction explaining that BioBANC na Gaillimhe is a multidisciplinary initiative based at the School of Medicine, University of Galway, which brings together expertise in biobanking with the aim of building an inclusive, patient-centered, and efficient research environment. The term “BioBANC” refers to the initiative, while the annual BioBANC Symposium is one of its key national engagement activities. Regarding the BnaG, it stands for BioBANC na Gaillimhe, the Irish term loosely translates to “Galway Biobank.” It is a locally used abbreviation and has been included in Figure 3 the visual summary of key recommendations from the panel discussion. R3. HSE (Health Service Executive) and IPPOSI (Irish Platform for Patient Organisations, Science and Industry) were spelled out at first mention and added both to the list of abbreviations. R4. VEVOX is an interactive live polling and audience engagement tool that was used during the panel discussion to enhance inclusivity and encourage real-time participation. A QR code linking to the VEVOX session was circulated by email to attendees in advance of the event (available at: https://stories.universityofgalway.ie/biobanc-na-gaillimhe-bnag3/index.html). Participants were able to respond via their devices, using both multiple-choice and free-text formats. The polling enabled instant feedback and inclusive engagement, with free-text responses automatically visualized as a word cloud to support discussion. R5. The “Quality Matters” session was indeed rich in content and aligned closely with the overarching goals of the symposium. To better contextualise its relevance, we have added a passage to the manuscript summarising the key presentations and their connection to biobanking standards and international collaboration. While the main focus of the paper remains the panel discussion and Ireland’s potential membership in BBMRI-ERIC, we agree that this session adds important depth to the national conversation around quality and best practices, and we appreciate the opportunity to clarify its contribution. R6. We thank the reviewer for this suggestion. The relevant section has now been revised to clarify that Biobank Ireland Trust, presented by Professor Richard Flavin (Trinity College/St James’s Hospital, Dublin), is an independent national charitable initiative that supports the development of biobanking throughout Ireland, with a particular focus on cancer research. It promotes collaboration through a federated model and encourages best practices in biobanking. Biobank Ireland Trust is also a member of the Mapping Ireland Biobanking Working Group and contributes to national discussions around biobanking infrastructure, including those highlighted at the BioBANC Symposium. We thank the reviewer for their thoughtful and encouraging feedback. We appreciate the valuable suggestions provided to improve clarity and coherence. We have addressed each of the points below: R1 and R2. To provide greater clarity, we have added a sentence early in the Introduction explaining that BioBANC na Gaillimhe is a multidisciplinary initiative based at the School of Medicine, University of Galway, which brings together expertise in biobanking with the aim of building an inclusive, patient-centered, and efficient research environment. The term “BioBANC” refers to the initiative, while the annual BioBANC Symposium is one of its key national engagement activities. Regarding the BnaG, it stands for BioBANC na Gaillimhe, the Irish term loosely translates to “Galway Biobank.” It is a locally used abbreviation and has been included in Figure 3 the visual summary of key recommendations from the panel discussion. R3. HSE (Health Service Executive) and IPPOSI (Irish Platform for Patient Organisations, Science and Industry) were spelled out at first mention and added both to the list of abbreviations. R4. VEVOX is an interactive live polling and audience engagement tool that was used during the panel discussion to enhance inclusivity and encourage real-time participation. A QR code linking to the VEVOX session was circulated by email to attendees in advance of the event (available at: https://stories.universityofgalway.ie/biobanc-na-gaillimhe-bnag3/index.html). Participants were able to respond via their devices, using both multiple-choice and free-text formats. The polling enabled instant feedback and inclusive engagement, with free-text responses automatically visualized as a word cloud to support discussion. R5. The “Quality Matters” session was indeed rich in content and aligned closely with the overarching goals of the symposium. To better contextualise its relevance, we have added a passage to the manuscript summarising the key presentations and their connection to biobanking standards and international collaboration. While the main focus of the paper remains the panel discussion and Ireland’s potential membership in BBMRI-ERIC, we agree that this session adds important depth to the national conversation around quality and best practices, and we appreciate the opportunity to clarify its contribution. R6. We thank the reviewer for this suggestion. The relevant section has now been revised to clarify that Biobank Ireland Trust, presented by Professor Richard Flavin (Trinity College/St James’s Hospital, Dublin), is an independent national charitable initiative that supports the development of biobanking throughout Ireland, with a particular focus on cancer research. It promotes collaboration through a federated model and encourages best practices in biobanking. Biobank Ireland Trust is also a member of the Mapping Ireland Biobanking Working Group and contributes to national discussions around biobanking infrastructure, including those highlighted at the BioBANC Symposium. Competing Interests: No competing interests were disclosed. Close Report a concern Respond or Comment COMMENTS ON THIS REPORT Author Response 03 Jun 2025 Amina Arar , Institute for Clinical Trials, School of Medicine, University of Galway, Galway, Ireland 03 Jun 2025 Author Response We thank the reviewer for their thoughtful and encouraging feedback. We appreciate the valuable suggestions provided to improve clarity and coherence. We have addressed each of the points below: ... Continue reading We thank the reviewer for their thoughtful and encouraging feedback. We appreciate the valuable suggestions provided to improve clarity and coherence. We have addressed each of the points below: R1 and R2. To provide greater clarity, we have added a sentence early in the Introduction explaining that BioBANC na Gaillimhe is a multidisciplinary initiative based at the School of Medicine, University of Galway, which brings together expertise in biobanking with the aim of building an inclusive, patient-centered, and efficient research environment. The term “BioBANC” refers to the initiative, while the annual BioBANC Symposium is one of its key national engagement activities. Regarding the BnaG, it stands for BioBANC na Gaillimhe, the Irish term loosely translates to “Galway Biobank.” It is a locally used abbreviation and has been included in Figure 3 the visual summary of key recommendations from the panel discussion. R3. HSE (Health Service Executive) and IPPOSI (Irish Platform for Patient Organisations, Science and Industry) were spelled out at first mention and added both to the list of abbreviations. R4. VEVOX is an interactive live polling and audience engagement tool that was used during the panel discussion to enhance inclusivity and encourage real-time participation. A QR code linking to the VEVOX session was circulated by email to attendees in advance of the event (available at: https://stories.universityofgalway.ie/biobanc-na-gaillimhe-bnag3/index.html). Participants were able to respond via their devices, using both multiple-choice and free-text formats. The polling enabled instant feedback and inclusive engagement, with free-text responses automatically visualized as a word cloud to support discussion. R5. The “Quality Matters” session was indeed rich in content and aligned closely with the overarching goals of the symposium. To better contextualise its relevance, we have added a passage to the manuscript summarising the key presentations and their connection to biobanking standards and international collaboration. While the main focus of the paper remains the panel discussion and Ireland’s potential membership in BBMRI-ERIC, we agree that this session adds important depth to the national conversation around quality and best practices, and we appreciate the opportunity to clarify its contribution. R6. We thank the reviewer for this suggestion. The relevant section has now been revised to clarify that Biobank Ireland Trust, presented by Professor Richard Flavin (Trinity College/St James’s Hospital, Dublin), is an independent national charitable initiative that supports the development of biobanking throughout Ireland, with a particular focus on cancer research. It promotes collaboration through a federated model and encourages best practices in biobanking. Biobank Ireland Trust is also a member of the Mapping Ireland Biobanking Working Group and contributes to national discussions around biobanking infrastructure, including those highlighted at the BioBANC Symposium. We thank the reviewer for their thoughtful and encouraging feedback. We appreciate the valuable suggestions provided to improve clarity and coherence. We have addressed each of the points below: R1 and R2. To provide greater clarity, we have added a sentence early in the Introduction explaining that BioBANC na Gaillimhe is a multidisciplinary initiative based at the School of Medicine, University of Galway, which brings together expertise in biobanking with the aim of building an inclusive, patient-centered, and efficient research environment. The term “BioBANC” refers to the initiative, while the annual BioBANC Symposium is one of its key national engagement activities. Regarding the BnaG, it stands for BioBANC na Gaillimhe, the Irish term loosely translates to “Galway Biobank.” It is a locally used abbreviation and has been included in Figure 3 the visual summary of key recommendations from the panel discussion. R3. HSE (Health Service Executive) and IPPOSI (Irish Platform for Patient Organisations, Science and Industry) were spelled out at first mention and added both to the list of abbreviations. R4. VEVOX is an interactive live polling and audience engagement tool that was used during the panel discussion to enhance inclusivity and encourage real-time participation. A QR code linking to the VEVOX session was circulated by email to attendees in advance of the event (available at: https://stories.universityofgalway.ie/biobanc-na-gaillimhe-bnag3/index.html). Participants were able to respond via their devices, using both multiple-choice and free-text formats. The polling enabled instant feedback and inclusive engagement, with free-text responses automatically visualized as a word cloud to support discussion. R5. The “Quality Matters” session was indeed rich in content and aligned closely with the overarching goals of the symposium. To better contextualise its relevance, we have added a passage to the manuscript summarising the key presentations and their connection to biobanking standards and international collaboration. While the main focus of the paper remains the panel discussion and Ireland’s potential membership in BBMRI-ERIC, we agree that this session adds important depth to the national conversation around quality and best practices, and we appreciate the opportunity to clarify its contribution. R6. We thank the reviewer for this suggestion. The relevant section has now been revised to clarify that Biobank Ireland Trust, presented by Professor Richard Flavin (Trinity College/St James’s Hospital, Dublin), is an independent national charitable initiative that supports the development of biobanking throughout Ireland, with a particular focus on cancer research. It promotes collaboration through a federated model and encourages best practices in biobanking. Biobank Ireland Trust is also a member of the Mapping Ireland Biobanking Working Group and contributes to national discussions around biobanking infrastructure, including those highlighted at the BioBANC Symposium. Competing Interests: No competing interests were disclosed. Close Report a concern COMMENT ON THIS REPORT Views 0 Cite How to cite this report: Kozlakidis Z. Reviewer Report For: A roadmap towards Ireland’s membership of BBMRI-ERIC [version 1; peer review: 1 approved, 3 approved with reservations] . HRB Open Res 2025, 8 :50 ( https://doi.org/10.21956/hrbopenres.15478.r46677 ) The direct URL for this report is: https://hrbopenresearch.org/articles/8-50/v1#referee-response-46677 NOTE: it is important to ensure the information in square brackets after the title is included in this citation. Close Copy Citation Details Reviewer Report 27 Apr 2025 Zisis Kozlakidis , International Agency for Research on Cancer, Rhone Alpes, France Approved with Reservations VIEWS 0 https://doi.org/10.21956/hrbopenres.15478.r46677 The article provides a well-structured summary of a panel discussion on biobanking that took place during the BIOBANC conference in Ireland, discussing Ireland's possibility of joining BBMRI-ERIC. - The experience with ECRIN is mentioned in the article, however, it ... Continue reading READ ALL The article provides a well-structured summary of a panel discussion on biobanking that took place during the BIOBANC conference in Ireland, discussing Ireland's possibility of joining BBMRI-ERIC. - The experience with ECRIN is mentioned in the article, however, it is not clear if this is the only ERIC that Ireland is a member of. It would be good to understand the extend to which Ireland participates to ERICs in general. - It would be good if Questions 1 and 4 could be shortened slightly. - In the discussion, it is not surprising that 100% of participants in a dedicated thematic conference are interested in the further development of that field. While it demonstrates clear interest, it should be counterbalanced in the knowledge that not all Irish biobanks/biobankers were represented. - Please provide the reference for the ISBER Best Practices and proficiency testing. - The discussion mentions "...panel advocated for immediate and proactive steps...", but no specific example is provided. Is the work clearly and accurately presented and does it cite the current literature? Yes Is the study design appropriate and is the work technically sound? Yes Are sufficient details of methods and analysis provided to allow replication by others? Yes If applicable, is the statistical analysis and its interpretation appropriate? Not applicable Are all the source data underlying the results available to ensure full reproducibility? Yes Are the conclusions drawn adequately supported by the results? Yes Competing Interests: No competing interests were disclosed. Reviewer Expertise: Laboratory infrastructure, biobanking, biobanking science, digital health. I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above. Close READ LESS CITE CITE HOW TO CITE THIS REPORT Kozlakidis Z. Reviewer Report For: A roadmap towards Ireland’s membership of BBMRI-ERIC [version 1; peer review: 1 approved, 3 approved with reservations] . HRB Open Res 2025, 8 :50 ( https://doi.org/10.21956/hrbopenres.15478.r46677 ) The direct URL for this report is: https://hrbopenresearch.org/articles/8-50/v1#referee-response-46677 NOTE: it is important to ensure the information in square brackets after the title is included in all citations of this article. COPY CITATION DETAILS Report a concern Author Response 03 Jul 2025 Amina Arar , Institute for Clinical Trials, School of Medicine, University of Galway, Galway, Ireland 03 Jul 2025 Author Response We thank the reviewer for their thoughtful feedback and helpful suggestions. We have addressed each point as follows: R1 . Regarding Ireland’s participation in other ERICs, in addition to ECRIN-ERIC, ... Continue reading We thank the reviewer for their thoughtful feedback and helpful suggestions. We have addressed each point as follows: R1 . Regarding Ireland’s participation in other ERICs, in addition to ECRIN-ERIC, Ireland is also a member of several other European Research Infrastructure Consortia. Notably, Ireland is a member of EATRIS-ERIC, which supports translational medicine by bridging the gap between laboratory research and clinical application. Ireland also participates in ERICs such as CESSDA-ERIC (social science data), ESS-ERIC (European Social Survey), EMSO-ERIC (marine observation), Euro-Argo ERIC (ocean profiling), and LOFAR ERIC (radio astronomy). However, we focused on ECRIN in this article as it plays the most relevant role in the context of clinical trials and biobanking, which is the primary subject of the paper. R2 . We acknowledge the reviewer’s comment. During the panel discussion, Questions 1 and 4 prompted particularly rich and detailed responses from the participants due to the significance of the topics. Question 1 addressed critical steps needed to map the Irish biobanking landscape, and question 4 explored valuable parallels with the clinical trials network ECRIN. We have aimed to preserve the depth of ideas shared while improving the overall readability. R3 . We thank the reviewer for this thoughtful and important observation. We acknowledge that while the polling results reflect strong interest among BioBANC Symposium attendees, the views captured represent a subset of the broader biobanking community in Ireland. To address this, a sentence has been added to the manuscript noting this limitation and clarifying that not all Irish biobanks or biobankers were present: “It should be noted that polling results reflect the views of participants who attended the symposium and may not represent the entire Irish biobanking landscape.” R4 . We thank the reviewer for highlighting the need to include a reference for ISBER Best Practices and the associated proficiency testing program. The citation for the ISBER Best Practices (Snapes et al., 2023) has been added (9,10), along with reference to the ISBER endorsed IBBL proficiency testing scheme (11,12). We also added two sentences to the "Quality Matters" section of the manuscript. “The ISBER-endorsed Biospecimen Proficiency Testing Program, provided by the Integrated Biobank of Luxembourg (IBBL) enables biorepositories to benchmark their performance against global peers, meet accreditation standards (e.g., ISO 20387, ISO 17025, CLIA), and continuously monitor and improve testing and processing accuracy (11, 12).” R5. We thank the reviewer for raising this point. In response, we are including a concrete recommendation from the roadmap below. Additionally, Figure 3 has been used to encapsulate the key takeaways from the panel discussion. Key Recommendations from the Roadmap: Join BBMRI-ERIC: Position Ireland as a full member of the European biobanking network. Integrate biobanking into the health system: Embed biobanking in national healthcare policies to support ongoing research. Secure infrastructure funding: Move beyond short-term grants to a sustainable funding model. Strengthen public and political understanding: Launch awareness campaigns to enhance trust and transparency. Create a national biobanking node: Coordinate efforts and standardise best practices across the country. We appreciate the reviewer’s expertise and constructive input, to improve the clarity of the paper. We thank the reviewer for their thoughtful feedback and helpful suggestions. We have addressed each point as follows: R1 . Regarding Ireland’s participation in other ERICs, in addition to ECRIN-ERIC, Ireland is also a member of several other European Research Infrastructure Consortia. Notably, Ireland is a member of EATRIS-ERIC, which supports translational medicine by bridging the gap between laboratory research and clinical application. Ireland also participates in ERICs such as CESSDA-ERIC (social science data), ESS-ERIC (European Social Survey), EMSO-ERIC (marine observation), Euro-Argo ERIC (ocean profiling), and LOFAR ERIC (radio astronomy). However, we focused on ECRIN in this article as it plays the most relevant role in the context of clinical trials and biobanking, which is the primary subject of the paper. R2 . We acknowledge the reviewer’s comment. During the panel discussion, Questions 1 and 4 prompted particularly rich and detailed responses from the participants due to the significance of the topics. Question 1 addressed critical steps needed to map the Irish biobanking landscape, and question 4 explored valuable parallels with the clinical trials network ECRIN. We have aimed to preserve the depth of ideas shared while improving the overall readability. R3 . We thank the reviewer for this thoughtful and important observation. We acknowledge that while the polling results reflect strong interest among BioBANC Symposium attendees, the views captured represent a subset of the broader biobanking community in Ireland. To address this, a sentence has been added to the manuscript noting this limitation and clarifying that not all Irish biobanks or biobankers were present: “It should be noted that polling results reflect the views of participants who attended the symposium and may not represent the entire Irish biobanking landscape.” R4 . We thank the reviewer for highlighting the need to include a reference for ISBER Best Practices and the associated proficiency testing program. The citation for the ISBER Best Practices (Snapes et al., 2023) has been added (9,10), along with reference to the ISBER endorsed IBBL proficiency testing scheme (11,12). We also added two sentences to the "Quality Matters" section of the manuscript. “The ISBER-endorsed Biospecimen Proficiency Testing Program, provided by the Integrated Biobank of Luxembourg (IBBL) enables biorepositories to benchmark their performance against global peers, meet accreditation standards (e.g., ISO 20387, ISO 17025, CLIA), and continuously monitor and improve testing and processing accuracy (11, 12).” R5. We thank the reviewer for raising this point. In response, we are including a concrete recommendation from the roadmap below. Additionally, Figure 3 has been used to encapsulate the key takeaways from the panel discussion. Key Recommendations from the Roadmap: Join BBMRI-ERIC: Position Ireland as a full member of the European biobanking network. Integrate biobanking into the health system: Embed biobanking in national healthcare policies to support ongoing research. Secure infrastructure funding: Move beyond short-term grants to a sustainable funding model. Strengthen public and political understanding: Launch awareness campaigns to enhance trust and transparency. Create a national biobanking node: Coordinate efforts and standardise best practices across the country. We appreciate the reviewer’s expertise and constructive input, to improve the clarity of the paper. Competing Interests: No competing interests were disclosed. Close Report a concern Respond or Comment COMMENTS ON THIS REPORT Author Response 03 Jul 2025 Amina Arar , Institute for Clinical Trials, School of Medicine, University of Galway, Galway, Ireland 03 Jul 2025 Author Response We thank the reviewer for their thoughtful feedback and helpful suggestions. We have addressed each point as follows: R1 . Regarding Ireland’s participation in other ERICs, in addition to ECRIN-ERIC, ... Continue reading We thank the reviewer for their thoughtful feedback and helpful suggestions. We have addressed each point as follows: R1 . Regarding Ireland’s participation in other ERICs, in addition to ECRIN-ERIC, Ireland is also a member of several other European Research Infrastructure Consortia. Notably, Ireland is a member of EATRIS-ERIC, which supports translational medicine by bridging the gap between laboratory research and clinical application. Ireland also participates in ERICs such as CESSDA-ERIC (social science data), ESS-ERIC (European Social Survey), EMSO-ERIC (marine observation), Euro-Argo ERIC (ocean profiling), and LOFAR ERIC (radio astronomy). However, we focused on ECRIN in this article as it plays the most relevant role in the context of clinical trials and biobanking, which is the primary subject of the paper. R2 . We acknowledge the reviewer’s comment. During the panel discussion, Questions 1 and 4 prompted particularly rich and detailed responses from the participants due to the significance of the topics. Question 1 addressed critical steps needed to map the Irish biobanking landscape, and question 4 explored valuable parallels with the clinical trials network ECRIN. We have aimed to preserve the depth of ideas shared while improving the overall readability. R3 . We thank the reviewer for this thoughtful and important observation. We acknowledge that while the polling results reflect strong interest among BioBANC Symposium attendees, the views captured represent a subset of the broader biobanking community in Ireland. To address this, a sentence has been added to the manuscript noting this limitation and clarifying that not all Irish biobanks or biobankers were present: “It should be noted that polling results reflect the views of participants who attended the symposium and may not represent the entire Irish biobanking landscape.” R4 . We thank the reviewer for highlighting the need to include a reference for ISBER Best Practices and the associated proficiency testing program. The citation for the ISBER Best Practices (Snapes et al., 2023) has been added (9,10), along with reference to the ISBER endorsed IBBL proficiency testing scheme (11,12). We also added two sentences to the "Quality Matters" section of the manuscript. “The ISBER-endorsed Biospecimen Proficiency Testing Program, provided by the Integrated Biobank of Luxembourg (IBBL) enables biorepositories to benchmark their performance against global peers, meet accreditation standards (e.g., ISO 20387, ISO 17025, CLIA), and continuously monitor and improve testing and processing accuracy (11, 12).” R5. We thank the reviewer for raising this point. In response, we are including a concrete recommendation from the roadmap below. Additionally, Figure 3 has been used to encapsulate the key takeaways from the panel discussion. Key Recommendations from the Roadmap: Join BBMRI-ERIC: Position Ireland as a full member of the European biobanking network. Integrate biobanking into the health system: Embed biobanking in national healthcare policies to support ongoing research. Secure infrastructure funding: Move beyond short-term grants to a sustainable funding model. Strengthen public and political understanding: Launch awareness campaigns to enhance trust and transparency. Create a national biobanking node: Coordinate efforts and standardise best practices across the country. We appreciate the reviewer’s expertise and constructive input, to improve the clarity of the paper. We thank the reviewer for their thoughtful feedback and helpful suggestions. We have addressed each point as follows: R1 . Regarding Ireland’s participation in other ERICs, in addition to ECRIN-ERIC, Ireland is also a member of several other European Research Infrastructure Consortia. Notably, Ireland is a member of EATRIS-ERIC, which supports translational medicine by bridging the gap between laboratory research and clinical application. Ireland also participates in ERICs such as CESSDA-ERIC (social science data), ESS-ERIC (European Social Survey), EMSO-ERIC (marine observation), Euro-Argo ERIC (ocean profiling), and LOFAR ERIC (radio astronomy). However, we focused on ECRIN in this article as it plays the most relevant role in the context of clinical trials and biobanking, which is the primary subject of the paper. R2 . We acknowledge the reviewer’s comment. During the panel discussion, Questions 1 and 4 prompted particularly rich and detailed responses from the participants due to the significance of the topics. Question 1 addressed critical steps needed to map the Irish biobanking landscape, and question 4 explored valuable parallels with the clinical trials network ECRIN. We have aimed to preserve the depth of ideas shared while improving the overall readability. R3 . We thank the reviewer for this thoughtful and important observation. We acknowledge that while the polling results reflect strong interest among BioBANC Symposium attendees, the views captured represent a subset of the broader biobanking community in Ireland. To address this, a sentence has been added to the manuscript noting this limitation and clarifying that not all Irish biobanks or biobankers were present: “It should be noted that polling results reflect the views of participants who attended the symposium and may not represent the entire Irish biobanking landscape.” R4 . We thank the reviewer for highlighting the need to include a reference for ISBER Best Practices and the associated proficiency testing program. The citation for the ISBER Best Practices (Snapes et al., 2023) has been added (9,10), along with reference to the ISBER endorsed IBBL proficiency testing scheme (11,12). We also added two sentences to the "Quality Matters" section of the manuscript. “The ISBER-endorsed Biospecimen Proficiency Testing Program, provided by the Integrated Biobank of Luxembourg (IBBL) enables biorepositories to benchmark their performance against global peers, meet accreditation standards (e.g., ISO 20387, ISO 17025, CLIA), and continuously monitor and improve testing and processing accuracy (11, 12).” R5. We thank the reviewer for raising this point. In response, we are including a concrete recommendation from the roadmap below. Additionally, Figure 3 has been used to encapsulate the key takeaways from the panel discussion. Key Recommendations from the Roadmap: Join BBMRI-ERIC: Position Ireland as a full member of the European biobanking network. Integrate biobanking into the health system: Embed biobanking in national healthcare policies to support ongoing research. Secure infrastructure funding: Move beyond short-term grants to a sustainable funding model. Strengthen public and political understanding: Launch awareness campaigns to enhance trust and transparency. Create a national biobanking node: Coordinate efforts and standardise best practices across the country. We appreciate the reviewer’s expertise and constructive input, to improve the clarity of the paper. Competing Interests: No competing interests were disclosed. Close Report a concern COMMENT ON THIS REPORT Views 0 Cite How to cite this report: Dewilde M. Reviewer Report For: A roadmap towards Ireland’s membership of BBMRI-ERIC [version 1; peer review: 1 approved, 3 approved with reservations] . HRB Open Res 2025, 8 :50 ( https://doi.org/10.21956/hrbopenres.15478.r46683 ) The direct URL for this report is: https://hrbopenresearch.org/articles/8-50/v1#referee-response-46683 NOTE: it is important to ensure the information in square brackets after the title is included in this citation. Close Copy Citation Details Reviewer Report 18 Apr 2025 Mieke Dewilde , Belgian Cancer Registry, Brussels, Belgium Approved VIEWS 0 https://doi.org/10.21956/hrbopenres.15478.r46683 In general, this is an important and clear article. I have some minor suggestions. In Introduction, alinea 3: ...through membership of the European Clinical Research Infrastructure Network (ECRIN) the European research infrastructure (ERIC) ...: ... Continue reading READ ALL In general, this is an important and clear article. I have some minor suggestions. In Introduction, alinea 3: ...through membership of the European Clinical Research Infrastructure Network (ECRIN) the European research infrastructure (ERIC) ...: this reads a bit difficult for a foreign speaker. Maybe add ..through membership of ...(ECRIN)... in the ... (ERIC)..., or: ... Through membership of ... the European Research Infrastructure Consortium (ERIC) - European Clinical Research Infrastructure Network (ECRIN). In Introduction, alinea 5: ..., ERIC Forum, which BBMRI-ERIC coordinates... I read this sentence as 'BBMRI-ERIC is coordinating the ERIC Forum', and I'm unsure if this is what is meant, when I look at ERIC Forum Executive Board - . Methods: The methodology used and thoroughness of the discussion is impressive, and the methods of capturing and recording the voices of the stakeholders are both effective and refreshing. Results, question 1, alinea 4: It would benefit clarity is PPI is first spelled out here instead of in the last alinea of the discussion. What does the acronym IPPOSI stand for? Discussion The discussion is thorough and nails the point. I'm delighted to read about the strong support to further promote networked biobanking and pursue BBMRI-ERIC membership. Alinea 6: .. ISBER Best Practices...: to ensure reader refer to the correct edition, it might be beneficial to include a reference to Snapes E, et al., 2023 (Ref 1) or ISBER Best Practices For Repositories - ISBER . Is the work clearly and accurately presented and does it cite the current literature? Yes Is the study design appropriate and is the work technically sound? Yes Are sufficient details of methods and analysis provided to allow replication by others? Yes If applicable, is the statistical analysis and its interpretation appropriate? Not applicable Are all the source data underlying the results available to ensure full reproducibility? No source data required Are the conclusions drawn adequately supported by the results? Yes References 1. Snapes E, Astrin JJ, Bertheussen Krüger N, Grossman GH, et al.: Updating International Society for Biological and Environmental Repositories Best Practices, Fifth Edition: A New Process for Relevance in an Evolving Landscape. Biopreserv Biobank . 2023; 21 (6): 537-546 PubMed Abstract | Publisher Full Text Competing Interests: No competing interests were disclosed. Reviewer Expertise: Biobanking operations, Biobanking quality management, BBMRI-ERIC membership as national node personnel, Biobanking norms and standards. I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard. Close READ LESS CITE CITE HOW TO CITE THIS REPORT Dewilde M. Reviewer Report For: A roadmap towards Ireland’s membership of BBMRI-ERIC [version 1; peer review: 1 approved, 3 approved with reservations] . HRB Open Res 2025, 8 :50 ( https://doi.org/10.21956/hrbopenres.15478.r46683 ) The direct URL for this report is: https://hrbopenresearch.org/articles/8-50/v1#referee-response-46683 NOTE: it is important to ensure the information in square brackets after the title is included in all citations of this article. COPY CITATION DETAILS Report a concern Author Response 03 Jun 2025 Amina Arar , Institute for Clinical Trials, School of Medicine, University of Galway, Galway, Ireland 03 Jun 2025 Author Response We thank the reviewer for their positive feedback and helpful suggestions. We have addressed all the points raised, as outlined below: R1. Introduction, Alinea 3: The sentence has now ... Continue reading We thank the reviewer for their positive feedback and helpful suggestions. We have addressed all the points raised, as outlined below: R1. Introduction, Alinea 3: The sentence has now been revised for clarity. It now reads: “…through membership of the European Clinical Research Infrastructure Network (ECRIN) within the European Research Infrastructure Consortium (ERIC)...” R2. Introduction, Alinea 5: The role of BBMRI-ERIC was clarified by rephrasing to: “ This network includes the ERIC Forum, which is administratively supported by BBMRI-ERIC, and other European Research Infrastructures in the field of health and life sciences.” R3. We thank the reviewer for this positive feedback. No changes were necessary in response to this comment. R4. Results – Question 1, Alinea 4: “Patient and Public Involvement (PPI)” has been spelt at the first mention and IPPOSI defined as the “Irish Platform for Patient Organisations, Science and Industry.” R5. Discussion, Alinea 6: The recommended reference to the ISBER Best Practices (Snapes et al., 2023) article and The ISBER Best Practices, Fifth Edition has been added. We thank the reviewer once again for their thoughtful review and support of the work. We thank the reviewer for their positive feedback and helpful suggestions. We have addressed all the points raised, as outlined below: R1. Introduction, Alinea 3: The sentence has now been revised for clarity. It now reads: “…through membership of the European Clinical Research Infrastructure Network (ECRIN) within the European Research Infrastructure Consortium (ERIC)...” R2. Introduction, Alinea 5: The role of BBMRI-ERIC was clarified by rephrasing to: “ This network includes the ERIC Forum, which is administratively supported by BBMRI-ERIC, and other European Research Infrastructures in the field of health and life sciences.” R3. We thank the reviewer for this positive feedback. No changes were necessary in response to this comment. R4. Results – Question 1, Alinea 4: “Patient and Public Involvement (PPI)” has been spelt at the first mention and IPPOSI defined as the “Irish Platform for Patient Organisations, Science and Industry.” R5. Discussion, Alinea 6: The recommended reference to the ISBER Best Practices (Snapes et al., 2023) article and The ISBER Best Practices, Fifth Edition has been added. We thank the reviewer once again for their thoughtful review and support of the work. Competing Interests: No competing interests were disclosed. Close Report a concern Respond or Comment COMMENTS ON THIS REPORT Author Response 03 Jun 2025 Amina Arar , Institute for Clinical Trials, School of Medicine, University of Galway, Galway, Ireland 03 Jun 2025 Author Response We thank the reviewer for their positive feedback and helpful suggestions. We have addressed all the points raised, as outlined below: R1. Introduction, Alinea 3: The sentence has now ... Continue reading We thank the reviewer for their positive feedback and helpful suggestions. We have addressed all the points raised, as outlined below: R1. Introduction, Alinea 3: The sentence has now been revised for clarity. It now reads: “…through membership of the European Clinical Research Infrastructure Network (ECRIN) within the European Research Infrastructure Consortium (ERIC)...” R2. Introduction, Alinea 5: The role of BBMRI-ERIC was clarified by rephrasing to: “ This network includes the ERIC Forum, which is administratively supported by BBMRI-ERIC, and other European Research Infrastructures in the field of health and life sciences.” R3. We thank the reviewer for this positive feedback. No changes were necessary in response to this comment. R4. Results – Question 1, Alinea 4: “Patient and Public Involvement (PPI)” has been spelt at the first mention and IPPOSI defined as the “Irish Platform for Patient Organisations, Science and Industry.” R5. Discussion, Alinea 6: The recommended reference to the ISBER Best Practices (Snapes et al., 2023) article and The ISBER Best Practices, Fifth Edition has been added. We thank the reviewer once again for their thoughtful review and support of the work. We thank the reviewer for their positive feedback and helpful suggestions. We have addressed all the points raised, as outlined below: R1. Introduction, Alinea 3: The sentence has now been revised for clarity. It now reads: “…through membership of the European Clinical Research Infrastructure Network (ECRIN) within the European Research Infrastructure Consortium (ERIC)...” R2. Introduction, Alinea 5: The role of BBMRI-ERIC was clarified by rephrasing to: “ This network includes the ERIC Forum, which is administratively supported by BBMRI-ERIC, and other European Research Infrastructures in the field of health and life sciences.” R3. We thank the reviewer for this positive feedback. No changes were necessary in response to this comment. R4. Results – Question 1, Alinea 4: “Patient and Public Involvement (PPI)” has been spelt at the first mention and IPPOSI defined as the “Irish Platform for Patient Organisations, Science and Industry.” R5. Discussion, Alinea 6: The recommended reference to the ISBER Best Practices (Snapes et al., 2023) article and The ISBER Best Practices, Fifth Edition has been added. We thank the reviewer once again for their thoughtful review and support of the work. Competing Interests: No competing interests were disclosed. Close Report a concern COMMENT ON THIS REPORT Comments on this article Comments (0) Version 2 VERSION 2 PUBLISHED 04 Apr 2025 ADD YOUR COMMENT Comment keyboard_arrow_left keyboard_arrow_right Open Peer Review Reviewer Status info_outline Alongside their report, reviewers assign a status to the article: Approved The paper is scientifically sound in its current form and only minor, if any, improvements are suggested Approved with reservations A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. Not approved Fundamental flaws in the paper seriously undermine the findings and conclusions Reviewer Reports Invited Reviewers 1 2 3 4 Version 2 (revision) 29 May 25 read read Version 1 04 Apr 25 read read read read Mieke Dewilde , Belgian Cancer Registry, Brussels, Belgium Zisis Kozlakidis , International Agency for Research on Cancer, Rhone Alpes, France Daniela Capello , University of Eastern Piedmont, Novara, Italy Andrea Wutte , BBMRI-ERIC, Korneuburg, Austria Comments on this article All Comments (0) Add a comment Sign up for content alerts Sign Up You are now signed up to receive this alert keyboard_arrow_left Back to all reports Reviewer Report 0 Views copyright © 2025 Capello D. This is an open access peer review report distributed under the terms of the Creative Commons Attribution License , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. 16 Jun 2025 | for Version 2 Daniela Capello , Department of Translational Medicine, University of Eastern Piedmont, Novara, Italy 0 Views copyright © 2025 Capello D. This is an open access peer review report distributed under the terms of the Creative Commons Attribution License , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. format_quote Cite this report speaker_notes Responses (0) Approved info_outline Alongside their report, reviewers assign a status to the article: Approved The paper is scientifically sound in its current form and only minor, if any, improvements are suggested Approved with reservations A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. Not approved Fundamental flaws in the paper seriously undermine the findings and conclusions Approved. No further comments. Congratulations on the work done Competing Interests No competing interests were disclosed. Reviewer Expertise Biobanking quality and sustainability, technical and ELSI aspects, public and patient engagement, population-based studies, biomarker discovery I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard. reply Respond to this report Responses (0) Capello D. Peer Review Report For: A roadmap towards Ireland’s membership of BBMRI-ERIC [version 1; peer review: 1 approved, 3 approved with reservations] . HRB Open Res 2025, 8 :50 ( https://doi.org/10.21956/hrbopenres.15585.r47511) NOTE: it is important to ensure the information in square brackets after the title is included in this citation. The direct URL for this report is: https://hrbopenresearch.org/articles/8-50/v2#referee-response-47511 keyboard_arrow_left Back to all reports Reviewer Report 0 Views copyright © 2025 Kozlakidis Z. This is an open access peer review report distributed under the terms of the Creative Commons Attribution License , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. 03 Jun 2025 | for Version 2 Zisis Kozlakidis , International Agency for Research on Cancer, Rhone Alpes, France 0 Views copyright © 2025 Kozlakidis Z. This is an open access peer review report distributed under the terms of the Creative Commons Attribution License , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. format_quote Cite this report speaker_notes Responses (0) Approved info_outline Alongside their report, reviewers assign a status to the article: Approved The paper is scientifically sound in its current form and only minor, if any, improvements are suggested Approved with reservations A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. Not approved Fundamental flaws in the paper seriously undermine the findings and conclusions No further comments. Competing Interests No competing interests were disclosed. Reviewer Expertise Laboratory infrastructure, biobanking, biobanking science, digital health. I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard. reply Respond to this report Responses (0) Kozlakidis Z. Peer Review Report For: A roadmap towards Ireland’s membership of BBMRI-ERIC [version 1; peer review: 1 approved, 3 approved with reservations] . HRB Open Res 2025, 8 :50 ( https://doi.org/10.21956/hrbopenres.15585.r47510) NOTE: it is important to ensure the information in square brackets after the title is included in this citation. The direct URL for this report is: https://hrbopenresearch.org/articles/8-50/v2#referee-response-47510 keyboard_arrow_left Back to all reports Reviewer Report 0 Views copyright © 2025 Wutte A. This is an open access peer review report distributed under the terms of the Creative Commons Attribution License , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. 30 Apr 2025 | for Version 1 Andrea Wutte , BBMRI-ERIC, Korneuburg, Austria 0 Views copyright © 2025 Wutte A. This is an open access peer review report distributed under the terms of the Creative Commons Attribution License , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. format_quote Cite this report speaker_notes Responses (0) Approved With Reservations info_outline Alongside their report, reviewers assign a status to the article: Approved The paper is scientifically sound in its current form and only minor, if any, improvements are suggested Approved with reservations A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. Not approved Fundamental flaws in the paper seriously undermine the findings and conclusions Notes to the authors: The manuscript is well written and gives the reader an good overview on the discussion during the BioBANC Symposium. Notes to: 1. Is the work clearly and accurately presented and does it cite the current literature? Reference #1 directs to a general EU Commission page on research infrastructures, while the text specifically mentions BBMRI-ERIC. This should be clarified, and a direct link to the BBMRI-ERIC website would be helpful. Reference #3 cites a dissertation referenced by Dr. Sonja Kahn. Is this dissertation publicly accessible? If so, please provide a direct link. References #2 and #5 point to the same source—are there any differences between them? If not, consider consolidating. Reference #7 should link to EU-AMRI, as per the text. The correct link is: https://eu-amri.org . Note to 2. If applicable, is the statistical analysis and its interpretation appropriate? In the discussion, the authors should provide reference figures (e.g., total number of audience polling = 100%) to clarify what the presented percentages represent. To reinforce the point raised in Question 1—“better define and map the biobanking landscape in Ireland”—the authors could explain how the audience’s affiliations (e.g., academia, hospitals) reflect the broader national landscape. Including national-level benchmarks would help contextualize the data in a bigger picture. For example, how representative is the symposium audience of the wider group of stakeholders who could benefit from initiatives like BioBANC hence would benefit from joining BBMRI-ERIC? Is the work clearly and accurately presented and does it cite the current literature? Partly Is the study design appropriate and is the work technically sound? Yes Are sufficient details of methods and analysis provided to allow replication by others? Yes If applicable, is the statistical analysis and its interpretation appropriate? Partly Are all the source data underlying the results available to ensure full reproducibility? Yes Are the conclusions drawn adequately supported by the results? Yes Competing Interests No competing interests were disclosed. Reviewer Expertise Biologist, certified Quality Manager, certified Lead auditor and technical assessor for Accreditation bodies (eg. Biobanking and Pre-analytical standards) . 10 y Experience in Biobanking and building a European biobank network. I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above. reply Respond to this report Responses (0) Wutte A. Peer Review Report For: A roadmap towards Ireland’s membership of BBMRI-ERIC [version 1; peer review: 1 approved, 3 approved with reservations] . HRB Open Res 2025, 8 :50 ( https://doi.org/10.21956/hrbopenres.15478.r46682) NOTE: it is important to ensure the information in square brackets after the title is included in this citation. The direct URL for this report is: https://hrbopenresearch.org/articles/8-50/v1#referee-response-46682 keyboard_arrow_left Back to all reports Reviewer Report 0 Views copyright © 2025 Capello D. This is an open access peer review report distributed under the terms of the Creative Commons Attribution License , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. 28 Apr 2025 | for Version 1 Daniela Capello , Department of Translational Medicine, University of Eastern Piedmont, Novara, Italy 0 Views copyright © 2025 Capello D. This is an open access peer review report distributed under the terms of the Creative Commons Attribution License , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. format_quote Cite this report speaker_notes Responses (1) Approved With Reservations info_outline Alongside their report, reviewers assign a status to the article: Approved The paper is scientifically sound in its current form and only minor, if any, improvements are suggested Approved with reservations A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. Not approved Fundamental flaws in the paper seriously undermine the findings and conclusions Overall, this is a well-written paper that highlights the scientific, ethical, and societal benefits of increasing awareness about biobanking and the opportunities that BBMRI-ERIC membership offers to enhance the quality and coherence of national efforts. In particular, the article underlines the potential for growth in scientific excellence, ethical governance, and community engagement. At the same time, it thoughtfully addresses key challenges, such as the limited political awareness, the fragmentation of the current biobanking landscape, and the importance of fostering greater public and patient understanding of their essential role in advancing research, primarily through biobanking. These considerations are relevant not only for countries like Ireland, which is in the process of joining BBMRI-ERIC, but also for member countries, which must continue to nurture awareness and uphold best practices to maximize the value of biobanking infrastructures. Here are a few suggestions for improvement: - The manuscript refers throughout to the “BioBANC Symposium” , but the term BioBANC itself is not clearly defined. It would be helpful to explain early in the text what BioBANC stands for—whether it is a formal initiative, a project, or a recurring event—and to clarify its role within the Irish biobanking community. - The abbreviation BnaG is listed among the abbreviations, but it is not used anywhere in the body of the manuscript. - The acronyms HSE and IPPOSI are used in the text but are not spelled out on first use, nor are they listed among the abbreviations. For clarity, particularly for international readers, please consider spelling out HSE and IPPOSI when they are first mentioned and including them in the list of acronyms. - VEVOX polling is mentioned multiple times and appears to have provided valuable real-time feedback during the symposium. However, the manuscript would benefit from a brief explanation of what VEVOX is, particularly for readers unfamiliar with the tool. It would also be helpful to include additional methodological details, for example, the number and type of questions posed (e.g., multiple-choice, free-text), the overall number of participants who responded, and how the responses were analyzed or summarized. This would provide helpful context for interpreting the visual elements (e.g., the word cloud) and the polling insights discussed in the results and discussion sections. Additional suggestions for improvement: The "Quality Matters" session in the Discussion section is briefly summarised through a list of names and contributions, but it would benefit from better contextualisation. Clarifying the objectives of this session, its relation to the overall symposium theme, and how it connects to the roadmap towards BBMRI-ERIC membership would help the reader better understand its relevance and impact. The brief reference to the Biobank Ireland Trust could also be more clearly linked to the rest of the article. Specifically, it would be helpful to clarify Biobank Ireland Trust's relationship to BioBANC na Gaillimhe or the national biobanking framework and whether it is part of the same strategic network or represents a complementary initiative. This would provide readers with a more cohesive understanding of the national landscape. Is the work clearly and accurately presented and does it cite the current literature? Yes Is the study design appropriate and is the work technically sound? Yes Are sufficient details of methods and analysis provided to allow replication by others? Yes If applicable, is the statistical analysis and its interpretation appropriate? Not applicable Are all the source data underlying the results available to ensure full reproducibility? No source data required Are the conclusions drawn adequately supported by the results? Yes Competing Interests No competing interests were disclosed. Reviewer Expertise Biobanking quality and sustainability, technical and ELSI aspects, public and patient engagement, population-based studies, biomarker discovery I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above. reply Respond to this report Responses (1) Author Response 03 Jun 2025 Amina Arar, Institute for Clinical Trials, School of Medicine, University of Galway, Galway, Ireland We thank the reviewer for their thoughtful and encouraging feedback. We appreciate the valuable suggestions provided to improve clarity and coherence. We have addressed each of the points below: R1 and R2. To provide greater clarity, we have added a sentence early in the Introduction explaining that BioBANC na Gaillimhe is a multidisciplinary initiative based at the School of Medicine, University of Galway, which brings together expertise in biobanking with the aim of building an inclusive, patient-centered, and efficient research environment. The term “BioBANC” refers to the initiative, while the annual BioBANC Symposium is one of its key national engagement activities. Regarding the BnaG, it stands for BioBANC na Gaillimhe, the Irish term loosely translates to “Galway Biobank.” It is a locally used abbreviation and has been included in Figure 3 the visual summary of key recommendations from the panel discussion. R3. HSE (Health Service Executive) and IPPOSI (Irish Platform for Patient Organisations, Science and Industry) were spelled out at first mention and added both to the list of abbreviations. R4. VEVOX is an interactive live polling and audience engagement tool that was used during the panel discussion to enhance inclusivity and encourage real-time participation. A QR code linking to the VEVOX session was circulated by email to attendees in advance of the event (available at: https://stories.universityofgalway.ie/biobanc-na-gaillimhe-bnag3/index.html). Participants were able to respond via their devices, using both multiple-choice and free-text formats. The polling enabled instant feedback and inclusive engagement, with free-text responses automatically visualized as a word cloud to support discussion. R5. The “Quality Matters” session was indeed rich in content and aligned closely with the overarching goals of the symposium. To better contextualise its relevance, we have added a passage to the manuscript summarising the key presentations and their connection to biobanking standards and international collaboration. While the main focus of the paper remains the panel discussion and Ireland’s potential membership in BBMRI-ERIC, we agree that this session adds important depth to the national conversation around quality and best practices, and we appreciate the opportunity to clarify its contribution. R6. We thank the reviewer for this suggestion. The relevant section has now been revised to clarify that Biobank Ireland Trust, presented by Professor Richard Flavin (Trinity College/St James’s Hospital, Dublin), is an independent national charitable initiative that supports the development of biobanking throughout Ireland, with a particular focus on cancer research. It promotes collaboration through a federated model and encourages best practices in biobanking. Biobank Ireland Trust is also a member of the Mapping Ireland Biobanking Working Group and contributes to national discussions around biobanking infrastructure, including those highlighted at the BioBANC Symposium. View more View less Competing Interests No competing interests were disclosed. reply Respond Report a concern Capello D. Peer Review Report For: A roadmap towards Ireland’s membership of BBMRI-ERIC [version 1; peer review: 1 approved, 3 approved with reservations] . HRB Open Res 2025, 8 :50 ( https://doi.org/10.21956/hrbopenres.15478.r46679) NOTE: it is important to ensure the information in square brackets after the title is included in this citation. The direct URL for this report is: https://hrbopenresearch.org/articles/8-50/v1#referee-response-46679 keyboard_arrow_left Back to all reports Reviewer Report 0 Views copyright © 2025 Kozlakidis Z. This is an open access peer review report distributed under the terms of the Creative Commons Attribution License , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. 27 Apr 2025 | for Version 1 Zisis Kozlakidis , International Agency for Research on Cancer, Rhone Alpes, France 0 Views copyright © 2025 Kozlakidis Z. This is an open access peer review report distributed under the terms of the Creative Commons Attribution License , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. format_quote Cite this report speaker_notes Responses (1) Approved With Reservations info_outline Alongside their report, reviewers assign a status to the article: Approved The paper is scientifically sound in its current form and only minor, if any, improvements are suggested Approved with reservations A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. Not approved Fundamental flaws in the paper seriously undermine the findings and conclusions The article provides a well-structured summary of a panel discussion on biobanking that took place during the BIOBANC conference in Ireland, discussing Ireland's possibility of joining BBMRI-ERIC. - The experience with ECRIN is mentioned in the article, however, it is not clear if this is the only ERIC that Ireland is a member of. It would be good to understand the extend to which Ireland participates to ERICs in general. - It would be good if Questions 1 and 4 could be shortened slightly. - In the discussion, it is not surprising that 100% of participants in a dedicated thematic conference are interested in the further development of that field. While it demonstrates clear interest, it should be counterbalanced in the knowledge that not all Irish biobanks/biobankers were represented. - Please provide the reference for the ISBER Best Practices and proficiency testing. - The discussion mentions "...panel advocated for immediate and proactive steps...", but no specific example is provided. Is the work clearly and accurately presented and does it cite the current literature? Yes Is the study design appropriate and is the work technically sound? Yes Are sufficient details of methods and analysis provided to allow replication by others? Yes If applicable, is the statistical analysis and its interpretation appropriate? Not applicable Are all the source data underlying the results available to ensure full reproducibility? Yes Are the conclusions drawn adequately supported by the results? Yes Competing Interests No competing interests were disclosed. Reviewer Expertise Laboratory infrastructure, biobanking, biobanking science, digital health. I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above. reply Respond to this report Responses (1) Author Response 03 Jul 2025 Amina Arar, Institute for Clinical Trials, School of Medicine, University of Galway, Galway, Ireland We thank the reviewer for their thoughtful feedback and helpful suggestions. We have addressed each point as follows: R1 . Regarding Ireland’s participation in other ERICs, in addition to ECRIN-ERIC, Ireland is also a member of several other European Research Infrastructure Consortia. Notably, Ireland is a member of EATRIS-ERIC, which supports translational medicine by bridging the gap between laboratory research and clinical application. Ireland also participates in ERICs such as CESSDA-ERIC (social science data), ESS-ERIC (European Social Survey), EMSO-ERIC (marine observation), Euro-Argo ERIC (ocean profiling), and LOFAR ERIC (radio astronomy). However, we focused on ECRIN in this article as it plays the most relevant role in the context of clinical trials and biobanking, which is the primary subject of the paper. R2 . We acknowledge the reviewer’s comment. During the panel discussion, Questions 1 and 4 prompted particularly rich and detailed responses from the participants due to the significance of the topics. Question 1 addressed critical steps needed to map the Irish biobanking landscape, and question 4 explored valuable parallels with the clinical trials network ECRIN. We have aimed to preserve the depth of ideas shared while improving the overall readability. R3 . We thank the reviewer for this thoughtful and important observation. We acknowledge that while the polling results reflect strong interest among BioBANC Symposium attendees, the views captured represent a subset of the broader biobanking community in Ireland. To address this, a sentence has been added to the manuscript noting this limitation and clarifying that not all Irish biobanks or biobankers were present: “It should be noted that polling results reflect the views of participants who attended the symposium and may not represent the entire Irish biobanking landscape.” R4 . We thank the reviewer for highlighting the need to include a reference for ISBER Best Practices and the associated proficiency testing program. The citation for the ISBER Best Practices (Snapes et al., 2023) has been added (9,10), along with reference to the ISBER endorsed IBBL proficiency testing scheme (11,12). We also added two sentences to the "Quality Matters" section of the manuscript. “The ISBER-endorsed Biospecimen Proficiency Testing Program, provided by the Integrated Biobank of Luxembourg (IBBL) enables biorepositories to benchmark their performance against global peers, meet accreditation standards (e.g., ISO 20387, ISO 17025, CLIA), and continuously monitor and improve testing and processing accuracy (11, 12).” R5. We thank the reviewer for raising this point. In response, we are including a concrete recommendation from the roadmap below. Additionally, Figure 3 has been used to encapsulate the key takeaways from the panel discussion. Key Recommendations from the Roadmap: Join BBMRI-ERIC: Position Ireland as a full member of the European biobanking network. Integrate biobanking into the health system: Embed biobanking in national healthcare policies to support ongoing research. Secure infrastructure funding: Move beyond short-term grants to a sustainable funding model. Strengthen public and political understanding: Launch awareness campaigns to enhance trust and transparency. Create a national biobanking node: Coordinate efforts and standardise best practices across the country. We appreciate the reviewer’s expertise and constructive input, to improve the clarity of the paper. View more View less Competing Interests No competing interests were disclosed. reply Respond Report a concern Kozlakidis Z. Peer Review Report For: A roadmap towards Ireland’s membership of BBMRI-ERIC [version 1; peer review: 1 approved, 3 approved with reservations] . HRB Open Res 2025, 8 :50 ( https://doi.org/10.21956/hrbopenres.15478.r46677) NOTE: it is important to ensure the information in square brackets after the title is included in this citation. The direct URL for this report is: https://hrbopenresearch.org/articles/8-50/v1#referee-response-46677 keyboard_arrow_left Back to all reports Reviewer Report 0 Views copyright © 2025 Dewilde M. This is an open access peer review report distributed under the terms of the Creative Commons Attribution License , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. 18 Apr 2025 | for Version 1 Mieke Dewilde , Belgian Cancer Registry, Brussels, Belgium 0 Views copyright © 2025 Dewilde M. This is an open access peer review report distributed under the terms of the Creative Commons Attribution License , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. format_quote Cite this report speaker_notes Responses (1) Approved info_outline Alongside their report, reviewers assign a status to the article: Approved The paper is scientifically sound in its current form and only minor, if any, improvements are suggested Approved with reservations A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. Not approved Fundamental flaws in the paper seriously undermine the findings and conclusions In general, this is an important and clear article. I have some minor suggestions. In Introduction, alinea 3: ...through membership of the European Clinical Research Infrastructure Network (ECRIN) the European research infrastructure (ERIC) ...: this reads a bit difficult for a foreign speaker. Maybe add ..through membership of ...(ECRIN)... in the ... (ERIC)..., or: ... Through membership of ... the European Research Infrastructure Consortium (ERIC) - European Clinical Research Infrastructure Network (ECRIN). In Introduction, alinea 5: ..., ERIC Forum, which BBMRI-ERIC coordinates... I read this sentence as 'BBMRI-ERIC is coordinating the ERIC Forum', and I'm unsure if this is what is meant, when I look at ERIC Forum Executive Board - . Methods: The methodology used and thoroughness of the discussion is impressive, and the methods of capturing and recording the voices of the stakeholders are both effective and refreshing. Results, question 1, alinea 4: It would benefit clarity is PPI is first spelled out here instead of in the last alinea of the discussion. What does the acronym IPPOSI stand for? Discussion The discussion is thorough and nails the point. I'm delighted to read about the strong support to further promote networked biobanking and pursue BBMRI-ERIC membership. Alinea 6: .. ISBER Best Practices...: to ensure reader refer to the correct edition, it might be beneficial to include a reference to Snapes E, et al., 2023 (Ref 1) or ISBER Best Practices For Repositories - ISBER . Is the work clearly and accurately presented and does it cite the current literature? Yes Is the study design appropriate and is the work technically sound? Yes Are sufficient details of methods and analysis provided to allow replication by others? Yes If applicable, is the statistical analysis and its interpretation appropriate? Not applicable Are all the source data underlying the results available to ensure full reproducibility? No source data required Are the conclusions drawn adequately supported by the results? Yes References 1. Snapes E, Astrin JJ, Bertheussen Krüger N, Grossman GH, et al.: Updating International Society for Biological and Environmental Repositories Best Practices, Fifth Edition: A New Process for Relevance in an Evolving Landscape. Biopreserv Biobank . 2023; 21 (6): 537-546 PubMed Abstract | Publisher Full Text Competing Interests No competing interests were disclosed. Reviewer Expertise Biobanking operations, Biobanking quality management, BBMRI-ERIC membership as national node personnel, Biobanking norms and standards. I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard. reply Respond to this report Responses (1) Author Response 03 Jun 2025 Amina Arar, Institute for Clinical Trials, School of Medicine, University of Galway, Galway, Ireland We thank the reviewer for their positive feedback and helpful suggestions. We have addressed all the points raised, as outlined below: R1. Introduction, Alinea 3: The sentence has now been revised for clarity. It now reads: “…through membership of the European Clinical Research Infrastructure Network (ECRIN) within the European Research Infrastructure Consortium (ERIC)...” R2. Introduction, Alinea 5: The role of BBMRI-ERIC was clarified by rephrasing to: “ This network includes the ERIC Forum, which is administratively supported by BBMRI-ERIC, and other European Research Infrastructures in the field of health and life sciences.” R3. We thank the reviewer for this positive feedback. No changes were necessary in response to this comment. R4. Results – Question 1, Alinea 4: “Patient and Public Involvement (PPI)” has been spelt at the first mention and IPPOSI defined as the “Irish Platform for Patient Organisations, Science and Industry.” R5. Discussion, Alinea 6: The recommended reference to the ISBER Best Practices (Snapes et al., 2023) article and The ISBER Best Practices, Fifth Edition has been added. We thank the reviewer once again for their thoughtful review and support of the work. View more View less Competing Interests No competing interests were disclosed. reply Respond Report a concern Dewilde M. Peer Review Report For: A roadmap towards Ireland’s membership of BBMRI-ERIC [version 1; peer review: 1 approved, 3 approved with reservations] . HRB Open Res 2025, 8 :50 ( https://doi.org/10.21956/hrbopenres.15478.r46683) NOTE: it is important to ensure the information in square brackets after the title is included in this citation. The direct URL for this report is: https://hrbopenresearch.org/articles/8-50/v1#referee-response-46683 Alongside their report, reviewers assign a status to the article: Approved - the paper is scientifically sound in its current form and only minor, if any, improvements are suggested Approved with reservations - A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. Not approved - fundamental flaws in the paper seriously undermine the findings and conclusions Adjust parameters to alter display View on desktop for interactive features Includes Interactive Elements View on desktop for interactive features Competing Interests Policy Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list: Examples of 'Non-Financial Competing Interests' Within the past 4 years, you have held joint grants, published or collaborated with any of the authors of the selected paper. You have a close personal relationship (e.g. parent, spouse, sibling, or domestic partner) with any of the authors. You are a close professional associate of any of the authors (e.g. scientific mentor, recent student). You work at the same institute as any of the authors. You hope/expect to benefit (e.g. favour or employment) as a result of your submission. You are an Editor for the journal in which the article is published. Examples of 'Financial Competing Interests' You expect to receive, or in the past 4 years have received, any of the following from any commercial organisation that may gain financially from your submission: a salary, fees, funding, reimbursements. You expect to receive, or in the past 4 years have received, shared grant support or other funding with any of the authors. You hold, or are currently applying for, any patents or significant stocks/shares relating to the subject matter of the paper you are commenting on. Stay Updated Sign up for content alerts and receive a weekly or monthly email with all newly published articles Register with HRB Open Research Already registered? Sign in Not now, thanks close PLEASE NOTE If you are an AUTHOR of this article, please check that you signed in with the account associated with this article otherwise we cannot automatically identify your role as an author and your comment will be labelled as a “User Comment”. If you are a REVIEWER of this article, please check that you have signed in with the account associated with this article and then go to your account to submit your report, please do not post your review here. If you do not have access to your original account, please contact us . All commenters must hold a formal affiliation as per our Policies . The information that you give us will be displayed next to your comment. User comments must be in English, comprehensible and relevant to the article under discussion. We reserve the right to remove any comments that we consider to be inappropriate, offensive or otherwise in breach of the User Comment Terms and Conditions . Commenters must not use a comment for personal attacks. When criticisms of the article are based on unpublished data, the data should be made available. I accept the User Comment Terms and Conditions Please confirm that you accept the User Comment Terms and Conditions. Affiliation ✕ refresh Please enter your institution. Note: To add your institution or organisation, start typing the name and then select the correct name from the list. Where applicable, the name will appear in both the original language and in English. Do not paste in the name. If the name does not appear in the drop-down list, we will display the information you have entered. ✕ refresh Country/Region * USA UK Canada China France Germany Afghanistan Aland Islands Albania Algeria American Samoa Andorra Angola Anguilla Antarctica Antigua and Barbuda Argentina Armenia Aruba Australia Austria Azerbaijan Bahamas Bahrain Bangladesh Barbados Belarus Belgium Belize Benin Bermuda Bhutan Bolivia Bosnia and Herzegovina Botswana Bouvet Island Brazil British Indian Ocean Territory British Virgin Islands Brunei Bulgaria Burkina Faso Burundi Cambodia Cameroon Canada Cape Verde Cayman Islands Central African Republic Chad Chile China Christmas Island Cocos (Keeling) Islands Colombia Comoros Congo Cook Islands Costa Rica Cote d'Ivoire Croatia Cuba Cyprus Czech Republic Democratic Republic of the Congo Denmark Djibouti Dominica Dominican Republic Ecuador Egypt El Salvador Equatorial Guinea Eritrea Estonia Ethiopia Falkland Islands Faroe Islands Federated States of Micronesia Fiji Finland France French Guiana French Polynesia French Southern Territories Gabon Georgia Germany Ghana Gibraltar Greece Greenland Grenada Guadeloupe Guam Guatemala Guernsey Guinea Guinea-Bissau Guyana Haiti Heard Island and Mcdonald Islands Holy See (Vatican City State) Honduras Hong Kong Hungary Iceland India Indonesia Iran Iraq Ireland Israel Italy Jamaica Japan Jersey Jordan Kazakhstan Kenya Kiribati Kosovo (Serbia and Montenegro) Kuwait Kyrgyzstan Lao People's Democratic Republic Latvia Lebanon Lesotho Liberia Libya Liechtenstein Lithuania Luxembourg Macao Madagascar Malawi Malaysia Maldives Mali Malta Marshall Islands Martinique Mauritania Mauritius Mayotte Mexico Minor Outlying Islands of the United States Moldova Monaco Mongolia Montenegro Montserrat Morocco Mozambique Myanmar Namibia Nauru Nepal Netherlands Antilles New Caledonia New Zealand Nicaragua Niger Nigeria Niue Norfolk Island North Korea North Macedonia Northern Mariana Islands Norway Oman Pakistan Palau Palestinian Territory Panama Papua New Guinea Paraguay Peru Philippines Pitcairn Poland Portugal Puerto Rico Qatar Reunion Romania Russian Federation Rwanda Saint Helena Saint Kitts and Nevis Saint Lucia Saint Pierre and Miquelon Saint Vincent and the Grenadines Samoa San Marino Sao Tome and Principe Saudi Arabia Senegal Serbia Seychelles Sierra Leone Singapore Slovakia Slovenia Solomon Islands Somalia South Africa South Georgia and the South Sandwich Is South Korea South Sudan Spain Sri Lanka Sudan Suriname Svalbard and Jan Mayen Swaziland Sweden Switzerland Syria Taiwan Tajikistan Tanzania Thailand The Gambia The Netherlands Timor-Leste Togo Tokelau Tonga Trinidad and Tobago Tunisia Turkey Turkmenistan Turks and Caicos Islands Tuvalu UK USA Uganda Ukraine United Arab Emirates United States Virgin Islands Uruguay Uzbekistan Vanuatu Venezuela Vietnam Wallis and Futuna West Bank and Gaza Strip Western Sahara Yemen Zambia Zimbabwe Please select your country/region. You must enter a comment. Competing Interests Please disclose any competing interests that might be construed to influence your judgment of the article's or peer review report's validity or importance. Competing Interests Policy Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list: Examples of 'Non-Financial Competing Interests' Within the past 4 years, you have held joint grants, published or collaborated with any of the authors of the selected paper. You have a close personal relationship (e.g. parent, spouse, sibling, or domestic partner) with any of the authors. You are a close professional associate of any of the authors (e.g. scientific mentor, recent student). You work at the same institute as any of the authors. You hope/expect to benefit (e.g. favour or employment) as a result of your submission. You are an Editor for the journal in which the article is published. Examples of 'Financial Competing Interests' You expect to receive, or in the past 4 years have received, any of the following from any commercial organisation that may gain financially from your submission: a salary, fees, funding, reimbursements. You expect to receive, or in the past 4 years have received, shared grant support or other funding with any of the authors. You hold, or are currently applying for, any patents or significant stocks/shares relating to the subject matter of the paper you are commenting on. Please state your competing interests The comment has been saved. An error has occurred. Please try again. Cancel Post var lTitle = "A roadmap towards Ireland\’s membership...".replace("'", ''); var linkedInUrl = "http://www.linkedin.com/shareArticle?url=https://hrbopenresearch.org/articles/8-50/v1" + "&title=" + encodeURIComponent(lTitle) + "&summary=" + encodeURIComponent('Read the article by '); var deliciousUrl = "https://del.icio.us/post?url=https://hrbopenresearch.org/articles/8-50/v1&title=" + encodeURIComponent(lTitle); var redditUrl = "http://reddit.com/submit?url=https://hrbopenresearch.org/articles/8-50/v1" + "&title=" + encodeURIComponent(lTitle); linkedInUrl += encodeURIComponent('Arar A et al.'); var offsetTop = /chrome/i.test( navigator.userAgent ) ? 4 : -10; var addthis_config = { ui_offset_top: offsetTop, services_compact : "facebook,twitter,www.linkedin.com,www.mendeley.com,reddit.com", services_expanded : "facebook,twitter,www.linkedin.com,www.mendeley.com,reddit.com", services_custom : [ { name: "LinkedIn", url: linkedInUrl, icon:"/img/icon/at_linkedin.svg" }, { name: "Mendeley", url: "http://www.mendeley.com/import/?url=https://hrbopenresearch.org/articles/8-50/v1/mendeley", icon:"/img/icon/at_mendeley.svg" }, { name: "Reddit", url: redditUrl, icon:"/img/icon/at_reddit.svg" }, ] }; var addthis_share = { url: "https://hrbopenresearch.org/articles/8-50", templates : { twitter : "A roadmap towards Ireland\’s membership of BBMRI-ERIC. Arar A et al., published by " + "@HRBOpenRes" + ", https://hrbopenresearch.org/articles/8-50/v1" } }; if (typeof(addthis) != "undefined"){ addthis.addEventListener('addthis.ready', checkCount); addthis.addEventListener('addthis.menu.share', checkCount); } $(".f1r-shares-twitter").attr("href", "https://twitter.com/intent/tweet?text=" + addthis_share.templates.twitter); $(".f1r-shares-facebook").attr("href", "https://www.facebook.com/sharer/sharer.php?u=" + addthis_share.url); $(".f1r-shares-linkedin").attr("href", addthis_config.services_custom[0].url); $(".f1r-shares-reddit").attr("href", addthis_config.services_custom[2].url); $(".f1r-shares-mendelay").attr("href", addthis_config.services_custom[1].url); function checkCount(){ setTimeout(function(){ $(".addthis_button_expanded").each(function(){ var count = $(this).text(); if (count !== "" && count != "0") $(this).removeClass("is-hidden"); else $(this).addClass("is-hidden"); }); }, 1000); } close How to cite this report {{reportCitation}} Cancel Copy Citation Details $(function(){R.ui.buttonDropdowns('.dropdown-for-downloads');}); $(function(){R.ui.toolbarDropdowns('.toolbar-dropdown-for-downloads');}); $.get("/articles/acj/14089/15478") new F1000.Clipboard(); new F1000.ThesaurusTermsDisplay("articles", "article", "15478"); $(document).ready(function() { $( "#frame1" ).on('load', function() { var mydiv = $(this).contents().find("div"); var h = mydiv.height(); console.log(h) }); var tooltipLivingFigure = jQuery(".interactive-living-figure-label .icon-more-info"), titleLivingFigure = tooltipLivingFigure.attr("title"); tooltipLivingFigure.simpletip({ fixed: true, position: ["-115", "30"], baseClass: 'small-tooltip', content:titleLivingFigure + " " }); tooltipLivingFigure.removeAttr("title"); $("body").on("click", ".cite-living-figure", function(e) { e.preventDefault(); var ref = $(this).attr("data-ref"); $(this).closest(".living-figure-list-container").find("#" + ref).fadeIn(200); }); $("body").on("click", ".close-cite-living-figure", function(e) { e.preventDefault(); $(this).closest(".popup-window-wrapper").fadeOut(200); }); $(document).on("mouseup", function(e) { var metricsContainer = $(".article-metrics-popover-wrapper"); if (!metricsContainer.is(e.target) && metricsContainer.has(e.target).length === 0) { $(".article-metrics-close-button").click(); } }); var articleId = $('#articleId').val(); if($("#main-article-count-box").attachArticleMetrics) { $("#main-article-count-box").attachArticleMetrics(articleId, { articleMetricsView: true }); } }); var figshareWidget = $(".new_figshare_widget"); if (figshareWidget.length > 0) { window.figshare.load("f1000", function(Widget) { // Select a tag/tags defined in your page. In this tag we will place the widget. _.map(figshareWidget, function(el){ var widget = new Widget({ articleId: $(el).attr("figshare_articleId") //height:300 // this is the height of the viewer part. [Default: 550] }); widget.initialize(); // initialize the widget widget.mount(el); // mount it in a tag that's on your page // this will save the widget on the global scope for later use from // your JS scripts. This line is optional. //window.widget = widget; }); }); } close Error Close Add Reset F1000.MICROSERVICES.AFFILIATION = ''; $(document).ready(function () { $('.js-affiliations-form').each((index, form) => { new AffiliationForm({ formId: form.id, institutionErrorSelector: '.comment-enter-institution', departmentErrorSelector: '.comment-enter-department', placeSelector: '.js-add-comment-place', stateSelector: '.js-add-comment-state', zipCodeSelector: '.js-add-comment-zipcode', countrySelector: '.js-add-comment-country', countryErrorSelector: '.comment-enter-country', }); }); }); $(document).ready(function () { var reportIds = { "47509": 0, "46677": 23, "47510": 14, "46678": 0, "47511": 7, "46679": 17, "47512": 0, "46680": 0, "46681": 0, "46682": 17, "46683": 27, "46684": 0, "46685": 0, "46686": 0, }; $(".referee-response-container,.js-referee-report").each(function(index, el) { var reportId = $(el).attr("data-reportid"), reportCount = reportIds[reportId] || 0; $(el).find(".comments-count-container,.js-referee-report-views").html(reportCount); }); var uuidInput = $("#article_uuid"), oldUUId = uuidInput.val(), newUUId = "9482915a-c2fc-44e4-a8f7-ab750a0eb8e9"; uuidInput.val(newUUId); $("a[href*='article_uuid=']").each(function(index, el) { var newHref = $(el).attr("href").replace(oldUUId, newUUId); $(el).attr("href", newHref); }); }); Are you a HRB-funded researcher? Submission to HRB Open Research is open to all HRB grantholders or people working on a HRB-funded/co-funded grant on or since 1 January 2017. Sign up for information about developments, publishing and publications from HRB Open Research. First Name * You must provide your first name Last Name * You must provide your last name Email * You must provide a valid email address Institution You must provide an institution. Submit Thank you! We'll keep you updated on any major new updates to HRB Open Research HRB Open Research Browse How to Publish About Contact RSS Cookie Notice Privacy Notice Legal Submit Your Research © F1000 Research Limited and its licensors ISSN 2515-4826 | Legal background var F1000platform = new F1000.Platform({ name: "hrb", displayName: "HRB Open Research", hostName: "hrbopenresearch.org", id: "5", editorialEmail: "[email protected]", infoEmail: "[email protected]" }); Sign In Remember me Forgotten your password? Sign In Cancel Email or password not correct. Please try again Please wait... $(function(){ // Note: All the setup needs to run against a name attribute and *not* the id due the clonish // nature of facebox... $("a[id=googleSignInButton]").click(function(event){ event.preventDefault(); $("input[id=oAuthSystem]").val("GOOGLE"); $("form[id=oAuthForm]").submit(); }); $("a[id=facebookSignInButton]").click(function(event){ event.preventDefault(); $("input[id=oAuthSystem]").val("FACEBOOK"); $("form[id=oAuthForm]").submit(); }); $("a[id=orcidSignInButton]").click(function(event){ event.preventDefault(); $("input[id=oAuthSystem]").val("ORCID"); $("form[id=oAuthForm]").submit(); }); }); If you've forgotten your password, please enter your email address below and we'll send you instructions on how to reset your password. The email address should be the one you originally registered with F1000. Email address not valid, please try again You registered with F1000 via Google, so we cannot reset your password. To sign in, please click here . If you still need help with your Google account password, please click here . You registered with F1000 via Facebook, so we cannot reset your password. To sign in, please click here . If you still need help with your Facebook account password, please click here . Code not correct, please try again Reset password Cancel Email us for further assistance. Server error, please try again. If your email address is registered with us, we will email you instructions to reset your password. If you think you should have received this email but it has not arrived, please check your spam filters and/or contact for further assistance. Please wait... Register $(document).ready(function () { signIn.createSignInAsRow($("#sign-in-form-gfb-popup")); $(".target-field").each(function () { var uris = $(this).val().split("/"); if (uris.pop() === "login") { $(this).val(uris.toString().replace(",","/")); } }); }); (function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'9feb6ab0a9d63fe2',t:'MTc3OTI4MDg5OA=='};var a=document.createElement('script');a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();